0000097745FALSE2022FYhttp://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpenseInvestments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationshttp://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationshttp://fasb.org/us-gaap/2022#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2022#OtherAssetsCurrent http://fasb.org/us-gaap/2022#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#OtherAssetsCurrenthttp://fasb.org/us-gaap/2022#OtherAssetsNoncurrent00000977452022-01-012022-12-310000097745us-gaap:CommonStockMember2022-01-012022-12-310000097745tmo:SeniorNotes0.75Due2024Member2022-01-012022-12-310000097745tmo:SeniorNotes0.125Due2025Member2022-01-012022-12-310000097745tmo:SeniorNotes200Due2025Member2022-01-012022-12-310000097745tmo:SeniorNotes3200Due2026Member2022-01-012022-12-310000097745tmo:SeniorNotes1.40Due2026Member2022-01-012022-12-310000097745tmo:A1.45SeniorNotesDue2027Member2022-01-012022-12-310000097745tmo:SeniorNotes175Due2027Member2022-01-012022-12-310000097745tmo:SeniorNotes0.500Due2028Member2022-01-012022-12-310000097745tmo:SeniorNotes1.375Due2028Member2022-01-012022-12-310000097745tmo:SeniorNotes1.95Due2029Member2022-01-012022-12-310000097745tmo:SeniorNotes0.875Due2031Member2022-01-012022-12-310000097745tmo:SeniorNotes2375Due2032Member2022-01-012022-12-310000097745tmo:SeniorNotes3650Due2034Member2022-01-012022-12-310000097745tmo:SeniorNotes2.875Due2037Member2022-01-012022-12-310000097745tmo:SeniorNotes1.500Due2039Member2022-01-012022-12-310000097745tmo:SeniorNotes1.875Due2049Member2022-01-012022-12-3100000977452022-07-01iso4217:USD00000977452023-02-04xbrli:shares00000977452022-12-3100000977452021-12-31iso4217:USDxbrli:shares0000097745us-gaap:ProductMember2022-01-012022-12-310000097745us-gaap:ProductMember2021-01-012021-12-310000097745us-gaap:ProductMember2020-01-012020-12-310000097745us-gaap:ServiceMember2022-01-012022-12-310000097745us-gaap:ServiceMember2021-01-012021-12-310000097745us-gaap:ServiceMember2020-01-012020-12-3100000977452021-01-012021-12-3100000977452020-01-012020-12-3100000977452020-12-3100000977452019-12-310000097745us-gaap:CommonStockMember2019-12-310000097745us-gaap:AdditionalPaidInCapitalMember2019-12-310000097745us-gaap:RetainedEarningsMember2019-12-310000097745us-gaap:TreasuryStockCommonMember2019-12-310000097745us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000097745us-gaap:ParentMember2019-12-310000097745us-gaap:NoncontrollingInterestMember2019-12-310000097745us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310000097745us-gaap:AccumulatedOtherComprehensiveIncomeMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310000097745us-gaap:ParentMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310000097745srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310000097745us-gaap:CommonStockMember2020-01-012020-12-310000097745us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310000097745us-gaap:TreasuryStockCommonMember2020-01-012020-12-310000097745us-gaap:ParentMember2020-01-012020-12-310000097745us-gaap:RetainedEarningsMember2020-01-012020-12-310000097745us-gaap:NoncontrollingInterestMember2020-01-012020-12-310000097745us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310000097745us-gaap:CommonStockMember2020-12-310000097745us-gaap:AdditionalPaidInCapitalMember2020-12-310000097745us-gaap:RetainedEarningsMember2020-12-310000097745us-gaap:TreasuryStockCommonMember2020-12-310000097745us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000097745us-gaap:ParentMember2020-12-310000097745us-gaap:NoncontrollingInterestMember2020-12-310000097745us-gaap:CommonStockMember2021-01-012021-12-310000097745us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310000097745us-gaap:TreasuryStockCommonMember2021-01-012021-12-310000097745us-gaap:ParentMember2021-01-012021-12-310000097745us-gaap:RetainedEarningsMember2021-01-012021-12-310000097745us-gaap:NoncontrollingInterestMember2021-01-012021-12-310000097745us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310000097745us-gaap:CommonStockMember2021-12-310000097745us-gaap:AdditionalPaidInCapitalMember2021-12-310000097745us-gaap:RetainedEarningsMember2021-12-310000097745us-gaap:TreasuryStockCommonMember2021-12-310000097745us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000097745us-gaap:ParentMember2021-12-310000097745us-gaap:NoncontrollingInterestMember2021-12-310000097745us-gaap:CommonStockMember2022-01-012022-12-310000097745us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310000097745us-gaap:TreasuryStockCommonMember2022-01-012022-12-310000097745us-gaap:ParentMember2022-01-012022-12-310000097745us-gaap:RetainedEarningsMember2022-01-012022-12-310000097745us-gaap:NoncontrollingInterestMember2022-01-012022-12-310000097745us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000097745us-gaap:CommonStockMember2022-12-310000097745us-gaap:AdditionalPaidInCapitalMember2022-12-310000097745us-gaap:RetainedEarningsMember2022-12-310000097745us-gaap:TreasuryStockCommonMember2022-12-310000097745us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000097745us-gaap:ParentMember2022-12-310000097745us-gaap:NoncontrollingInterestMember2022-12-310000097745tmo:PPDSNBLKKMember2022-12-31xbrli:pure0000097745us-gaap:ChangeInAccountingPrincipleOtherMember2021-09-300000097745us-gaap:ChangeInAccountingPrincipleOtherMember2021-10-020000097745us-gaap:ProductMemberus-gaap:ChangeInAccountingPrincipleOtherMember2021-07-042021-10-020000097745tmo:LaboratoryProductsandServicesMemberus-gaap:ChangeInAccountingPrincipleOtherMember2021-10-020000097745us-gaap:ProductMembertmo:LaboratoryProductsandServicesMemberus-gaap:ChangeInAccountingPrincipleOtherMember2021-07-042021-10-020000097745us-gaap:ChangeInAccountingPrincipleOtherMembertmo:SpecialtyDiagnosticsMember2021-10-020000097745us-gaap:ProductMemberus-gaap:ChangeInAccountingPrincipleOtherMembertmo:SpecialtyDiagnosticsMember2021-07-042021-10-020000097745us-gaap:BuildingAndBuildingImprovementsMembersrt:MinimumMember2022-01-012022-12-310000097745us-gaap:BuildingAndBuildingImprovementsMembersrt:MaximumMember2022-01-012022-12-310000097745us-gaap:MachineryAndEquipmentMembersrt:MinimumMember2022-01-012022-12-310000097745us-gaap:MachineryAndEquipmentMembersrt:MaximumMember2022-01-012022-12-310000097745us-gaap:LandMember2022-12-310000097745us-gaap:LandMember2021-12-310000097745us-gaap:BuildingAndBuildingImprovementsMember2022-12-310000097745us-gaap:BuildingAndBuildingImprovementsMember2021-12-310000097745us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember2022-12-310000097745us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember2021-12-310000097745us-gaap:ConstructionInProgressMember2022-12-310000097745us-gaap:ConstructionInProgressMember2021-12-310000097745srt:MaximumMember2022-01-012022-12-310000097745us-gaap:CustomerRelationshipsMember2022-12-310000097745us-gaap:CustomerRelationshipsMember2021-12-310000097745us-gaap:DevelopedTechnologyRightsMember2022-12-310000097745us-gaap:DevelopedTechnologyRightsMember2021-12-310000097745us-gaap:TradeNamesMember2022-12-310000097745us-gaap:TradeNamesMember2021-12-310000097745us-gaap:OrderOrProductionBacklogMember2022-12-310000097745us-gaap:OrderOrProductionBacklogMember2021-12-310000097745us-gaap:TradeNamesMember2022-12-310000097745us-gaap:TradeNamesMember2021-12-310000097745tmo:LifeSciencesSolutionsMember2020-12-310000097745tmo:AnalyticalInstrumentsMember2020-12-310000097745tmo:SpecialtyDiagnosticsMember2020-12-310000097745tmo:LaboratoryProductsandServicesMember2020-12-310000097745tmo:LifeSciencesSolutionsMember2021-01-012021-12-310000097745tmo:AnalyticalInstrumentsMember2021-01-012021-12-310000097745tmo:SpecialtyDiagnosticsMember2021-01-012021-12-310000097745tmo:LaboratoryProductsandServicesMember2021-01-012021-12-310000097745tmo:LifeSciencesSolutionsMember2021-12-310000097745tmo:AnalyticalInstrumentsMember2021-12-310000097745tmo:SpecialtyDiagnosticsMember2021-12-310000097745tmo:LaboratoryProductsandServicesMember2021-12-310000097745tmo:LifeSciencesSolutionsMember2022-01-012022-12-310000097745tmo:AnalyticalInstrumentsMember2022-01-012022-12-310000097745tmo:SpecialtyDiagnosticsMember2022-01-012022-12-310000097745tmo:LaboratoryProductsandServicesMember2022-01-012022-12-310000097745tmo:LifeSciencesSolutionsMember2022-12-310000097745tmo:AnalyticalInstrumentsMember2022-12-310000097745tmo:SpecialtyDiagnosticsMember2022-12-310000097745tmo:LaboratoryProductsandServicesMember2022-12-310000097745us-gaap:AccountingStandardsUpdate201613Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2020-01-010000097745us-gaap:SubsequentEventMembertmo:TheBindingSiteGroupMember2023-01-032023-01-030000097745us-gaap:SubsequentEventMembertmo:TheBindingSiteGroupMember2023-01-030000097745tmo:EuropeanViralVectorManufacturingBusinessMember2021-01-150000097745tmo:MesaBiotechMember2021-02-250000097745tmo:CSLMember2021-09-300000097745tmo:PPDIncMember2021-12-080000097745tmo:PeproTechIncMember2021-12-300000097745tmo:PPDIncMember2021-12-082021-12-080000097745tmo:PeproTechIncMember2021-12-302021-12-300000097745tmo:EuropeanViralVectorManufacturingBusinessMember2021-01-152021-01-150000097745tmo:MesaBiotechMember2021-02-252021-02-250000097745tmo:CSLMember2021-09-302021-09-300000097745us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2021-01-012021-12-310000097745us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2021-12-310000097745us-gaap:CustomerRelationshipsMembertmo:PPDIncMember2021-12-080000097745tmo:PeproTechIncMemberus-gaap:CustomerRelationshipsMember2021-12-300000097745tmo:EuropeanViralVectorManufacturingBusinessMemberus-gaap:CustomerRelationshipsMember2021-01-150000097745tmo:MesaBiotechMemberus-gaap:CustomerRelationshipsMember2021-02-250000097745us-gaap:CustomerRelationshipsMembertmo:CSLMember2021-09-300000097745us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberus-gaap:CustomerRelationshipsMember2021-12-310000097745us-gaap:DevelopedTechnologyRightsMembertmo:PPDIncMember2021-12-080000097745us-gaap:DevelopedTechnologyRightsMembertmo:PeproTechIncMember2021-12-300000097745us-gaap:DevelopedTechnologyRightsMembertmo:EuropeanViralVectorManufacturingBusinessMember2021-01-150000097745us-gaap:DevelopedTechnologyRightsMembertmo:MesaBiotechMember2021-02-250000097745us-gaap:DevelopedTechnologyRightsMembertmo:CSLMember2021-09-300000097745us-gaap:DevelopedTechnologyRightsMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2021-12-310000097745us-gaap:TradeNamesMembertmo:PPDIncMember2021-12-080000097745us-gaap:TradeNamesMembertmo:PeproTechIncMember2021-12-300000097745tmo:EuropeanViralVectorManufacturingBusinessMemberus-gaap:TradeNamesMember2021-01-150000097745tmo:MesaBiotechMemberus-gaap:TradeNamesMember2021-02-250000097745us-gaap:TradeNamesMembertmo:CSLMember2021-09-300000097745us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberus-gaap:TradeNamesMember2021-12-310000097745us-gaap:OrderOrProductionBacklogMembertmo:PPDIncMember2021-12-080000097745us-gaap:CustomerRelationshipsMember2021-01-012021-12-310000097745us-gaap:DevelopedTechnologyRightsMember2021-01-012021-12-310000097745us-gaap:TradeNamesMember2021-01-012021-12-310000097745us-gaap:OrderOrProductionBacklogMember2021-01-012021-12-310000097745tmo:PPDIncMember2021-01-012021-12-310000097745tmo:PPDIncMember2020-01-012020-12-310000097745tmo:PPDIncMemberus-gaap:AcquisitionRelatedCostsMember2021-01-012021-12-310000097745tmo:PPDIncMemberus-gaap:AcquisitionRelatedCostsMember2020-01-012020-12-310000097745tmo:ConsumablesMember2022-01-012022-12-310000097745tmo:ConsumablesMember2021-01-012021-12-310000097745tmo:ConsumablesMember2020-01-012020-12-310000097745tmo:InstrumentsMember2022-01-012022-12-310000097745tmo:InstrumentsMember2021-01-012021-12-310000097745tmo:InstrumentsMember2020-01-012020-12-310000097745srt:NorthAmericaMember2022-01-012022-12-310000097745srt:NorthAmericaMember2021-01-012021-12-310000097745srt:NorthAmericaMember2020-01-012020-12-310000097745srt:EuropeMember2022-01-012022-12-310000097745srt:EuropeMember2021-01-012021-12-310000097745srt:EuropeMember2020-01-012020-12-310000097745srt:AsiaPacificMember2022-01-012022-12-310000097745srt:AsiaPacificMember2021-01-012021-12-310000097745srt:AsiaPacificMember2020-01-012020-12-310000097745tmo:OtherRegionsMember2022-01-012022-12-310000097745tmo:OtherRegionsMember2021-01-012021-12-310000097745tmo:OtherRegionsMember2020-01-012020-12-3100000977452023-01-012022-12-31tmo:Segment0000097745us-gaap:OperatingSegmentsMembertmo:LifeSciencesSolutionsMember2022-01-012022-12-310000097745us-gaap:OperatingSegmentsMembertmo:LifeSciencesSolutionsMember2021-01-012021-12-310000097745us-gaap:OperatingSegmentsMembertmo:LifeSciencesSolutionsMember2020-01-012020-12-310000097745us-gaap:OperatingSegmentsMembertmo:AnalyticalInstrumentsMember2022-01-012022-12-310000097745us-gaap:OperatingSegmentsMembertmo:AnalyticalInstrumentsMember2021-01-012021-12-310000097745us-gaap:OperatingSegmentsMembertmo:AnalyticalInstrumentsMember2020-01-012020-12-310000097745us-gaap:OperatingSegmentsMembertmo:SpecialtyDiagnosticsMember2022-01-012022-12-310000097745us-gaap:OperatingSegmentsMembertmo:SpecialtyDiagnosticsMember2021-01-012021-12-310000097745us-gaap:OperatingSegmentsMembertmo:SpecialtyDiagnosticsMember2020-01-012020-12-310000097745us-gaap:OperatingSegmentsMembertmo:LaboratoryProductsandServicesMember2022-01-012022-12-310000097745us-gaap:OperatingSegmentsMembertmo:LaboratoryProductsandServicesMember2021-01-012021-12-310000097745us-gaap:OperatingSegmentsMembertmo:LaboratoryProductsandServicesMember2020-01-012020-12-310000097745us-gaap:IntersegmentEliminationMember2022-01-012022-12-310000097745us-gaap:IntersegmentEliminationMember2021-01-012021-12-310000097745us-gaap:IntersegmentEliminationMember2020-01-012020-12-310000097745us-gaap:OperatingSegmentsMember2022-01-012022-12-310000097745us-gaap:OperatingSegmentsMember2021-01-012021-12-310000097745us-gaap:OperatingSegmentsMember2020-01-012020-12-310000097745us-gaap:MaterialReconcilingItemsMember2022-01-012022-12-310000097745us-gaap:MaterialReconcilingItemsMember2021-01-012021-12-310000097745us-gaap:MaterialReconcilingItemsMember2020-01-012020-12-310000097745us-gaap:CorporateAndOtherMember2022-12-310000097745us-gaap:CorporateAndOtherMember2021-12-310000097745us-gaap:CorporateAndOtherMember2020-12-310000097745tmo:LifeSciencesSolutionsMember2020-01-012020-12-310000097745tmo:AnalyticalInstrumentsMember2020-01-012020-12-310000097745tmo:SpecialtyDiagnosticsMember2020-01-012020-12-310000097745tmo:LaboratoryProductsandServicesMember2020-01-012020-12-310000097745us-gaap:CorporateAndOtherMember2022-01-012022-12-310000097745us-gaap:CorporateAndOtherMember2021-01-012021-12-310000097745us-gaap:CorporateAndOtherMember2020-01-012020-12-310000097745country:US2022-01-012022-12-310000097745country:US2021-01-012021-12-310000097745country:US2020-01-012020-12-310000097745country:CN2022-01-012022-12-310000097745country:CN2021-01-012021-12-310000097745country:CN2020-01-012020-12-310000097745tmo:AllOtherCountriesMember2022-01-012022-12-310000097745tmo:AllOtherCountriesMember2021-01-012021-12-310000097745tmo:AllOtherCountriesMember2020-01-012020-12-310000097745country:US2022-12-310000097745country:US2021-12-310000097745country:US2020-12-310000097745tmo:AllOtherCountriesMember2022-12-310000097745tmo:AllOtherCountriesMember2021-12-310000097745tmo:AllOtherCountriesMember2020-12-310000097745us-gaap:InterestRateSwapMemberus-gaap:OtherExpenseMemberus-gaap:CashFlowHedgingMember2020-01-012020-12-310000097745us-gaap:EmployeeStockOptionMembersrt:MinimumMember2022-01-012022-12-310000097745srt:MaximumMemberus-gaap:EmployeeStockOptionMember2022-01-012022-12-310000097745us-gaap:EmployeeStockOptionMember2022-12-310000097745us-gaap:EmployeeStockOptionMember2022-01-012022-12-310000097745us-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMember2022-01-012022-12-310000097745us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2022-01-012022-12-310000097745us-gaap:RestrictedStockUnitsRSUMember2022-12-310000097745us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310000097745srt:MinimumMember2022-12-310000097745srt:MaximumMember2022-12-310000097745country:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745country:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745country:USus-gaap:PensionPlansDefinedBenefitMember2020-12-310000097745us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000097745country:USus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-310000097745country:USus-gaap:PensionPlansDefinedBenefitMember2021-01-012021-12-310000097745us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-310000097745us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-01-012021-12-310000097745us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-01-012020-12-310000097745country:USus-gaap:PensionPlansDefinedBenefitMember2020-01-012020-12-310000097745us-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745tmo:USEquityFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745country:USus-gaap:PensionPlansDefinedBenefitMembertmo:InternationalEquityFundsMember2022-12-310000097745us-gaap:FixedIncomeFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745srt:MinimumMemberus-gaap:EquityFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745srt:MaximumMemberus-gaap:EquityFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FixedIncomeFundsMembersrt:MinimumMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745srt:MaximumMemberus-gaap:FixedIncomeFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745srt:MinimumMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembertmo:MultiassetFundsMember2022-12-310000097745srt:MaximumMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembertmo:MultiassetFundsMember2022-12-310000097745us-gaap:DefinedBenefitPlanDerivativeMembersrt:MinimumMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:DefinedBenefitPlanDerivativeMembersrt:MaximumMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueInputsLevel1Membertmo:USEquityFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745tmo:USEquityFundsMembercountry:USus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueInputsLevel3Membertmo:USEquityFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembertmo:USEquityFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMembertmo:InternationalEquityFundsMember2022-12-310000097745country:USus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMembertmo:InternationalEquityFundsMember2022-12-310000097745us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMembertmo:InternationalEquityFundsMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMembertmo:InternationalEquityFundsMember2022-12-310000097745us-gaap:FixedIncomeFundsMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FixedIncomeFundsMembercountry:USus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:FixedIncomeFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:FixedIncomeFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:MoneyMarketFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:MoneyMarketFundsMembercountry:USus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:MoneyMarketFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745country:USus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:EquityFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:EquityFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:EquityFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:EquityFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:EquityFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FixedIncomeFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FixedIncomeFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FixedIncomeFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:FixedIncomeFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:FixedIncomeFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembertmo:MultiassetFundsMember2022-12-310000097745us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembertmo:MultiassetFundsMember2022-12-310000097745us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembertmo:MultiassetFundsMember2022-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembertmo:MultiassetFundsMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembertmo:MultiassetFundsMember2022-12-310000097745us-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745tmo:InsuranceContractsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745tmo:InsuranceContractsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745tmo:InsuranceContractsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueInputsLevel3Membertmo:InsuranceContractsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembertmo:InsuranceContractsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000097745tmo:USEquityFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel1Membertmo:USEquityFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745tmo:USEquityFundsMembercountry:USus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel3Membertmo:USEquityFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembertmo:USEquityFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745country:USus-gaap:PensionPlansDefinedBenefitMembertmo:InternationalEquityFundsMember2021-12-310000097745us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMembertmo:InternationalEquityFundsMember2021-12-310000097745country:USus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMembertmo:InternationalEquityFundsMember2021-12-310000097745us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMembertmo:InternationalEquityFundsMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMembertmo:InternationalEquityFundsMember2021-12-310000097745us-gaap:FixedIncomeFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FixedIncomeFundsMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FixedIncomeFundsMembercountry:USus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:FixedIncomeFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:FixedIncomeFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:MoneyMarketFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:MoneyMarketFundsMembercountry:USus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:MoneyMarketFundsMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745country:USus-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:EquityFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:EquityFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:EquityFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:EquityFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:EquityFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FixedIncomeFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FixedIncomeFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FixedIncomeFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:FixedIncomeFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:FixedIncomeFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:HedgeFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:HedgeFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:HedgeFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:HedgeFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:HedgeFundsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembertmo:MultiassetFundsMember2021-12-310000097745us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembertmo:MultiassetFundsMember2021-12-310000097745us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembertmo:MultiassetFundsMember2021-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembertmo:MultiassetFundsMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembertmo:MultiassetFundsMember2021-12-310000097745us-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745tmo:AlternativeInvestmentsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745tmo:AlternativeInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745tmo:AlternativeInvestmentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel3Membertmo:AlternativeInvestmentsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembertmo:AlternativeInvestmentsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745tmo:InsuranceContractsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745tmo:InsuranceContractsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745tmo:InsuranceContractsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel3Membertmo:InsuranceContractsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembertmo:InsuranceContractsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000097745us-gaap:DomesticCountryMember2022-01-012022-12-310000097745us-gaap:DomesticCountryMember2022-12-310000097745tmo:DeferredTaxImplicationsMember2021-01-012021-12-310000097745tmo:CapitalLossMember2021-01-012021-12-310000097745us-gaap:DomesticCountryMember2020-01-012020-12-310000097745us-gaap:DomesticCountryMember2020-12-310000097745tmo:DeferredTaxAssetInterestCarryforwardMember2020-01-012020-12-310000097745us-gaap:DomesticCountryMember2022-12-310000097745us-gaap:StateAndLocalJurisdictionMember2022-12-310000097745us-gaap:ForeignCountryMember2022-12-310000097745tmo:DomesticNOLExpiresMember2022-12-310000097745tmo:ForeignCountryNolExpiresMember2022-12-310000097745tmo:ForeignTaxCreditCarryforwardsMember2022-12-310000097745tmo:DeferredTaxAssetInterestCarryforwardMember2022-12-310000097745tmo:ForeignTaxPositionsMember2022-01-012022-12-310000097745tmo:FederalAndStateMember2022-01-012022-12-310000097745tmo:ForeignTaxPositionsMember2021-01-012021-12-310000097745tmo:FederalAndStateMember2021-01-012021-12-310000097745tmo:ForeignTaxPositionsMember2020-01-012020-12-310000097745tmo:FederalAndStateMember2020-01-012020-12-310000097745us-gaap:CommercialPaperMember2022-12-310000097745us-gaap:CommercialPaperMember2021-12-310000097745tmo:FloatingRateSOFR03518MonthSeniorNotesDue2023Memberus-gaap:SeniorNotesMember2022-01-012022-12-310000097745tmo:FloatingRateSOFR03518MonthSeniorNotesDue2023Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:FloatingRateSOFR03518MonthSeniorNotesDue2023Memberus-gaap:SeniorNotesMember2021-12-310000097745us-gaap:SeniorNotesMembertmo:FloatingRateSOFR039SeniorNotesDue2023Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:FloatingRateSOFR039SeniorNotesDue2023Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:FloatingRateSOFR039SeniorNotesDue2023Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0797Due2023Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0797Due2023Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0797Due2023Member2021-12-310000097745tmo:FloatingRate2YearSeniorNotesDue2023Memberus-gaap:SeniorNotesMember2022-01-012022-12-310000097745tmo:FloatingRate2YearSeniorNotesDue2023Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:FloatingRate2YearSeniorNotesDue2023Memberus-gaap:SeniorNotesMember2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0000Due2023Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0000Due2023Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0000Due2023Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0.75Due2024Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0.75Due2024Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0.75Due2024Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:FloatingRateSOFR053SeniorNotesDue2024Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:FloatingRateSOFR053SeniorNotesDue2024Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:FloatingRateSOFR053SeniorNotesDue2024Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1215Due2024Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1215Due2024Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1215Due2024Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0.125Due2025Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0.125Due2025Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0.125Due2025Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes200Due2025Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes200Due2025Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes200Due2025Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0853Due2025Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0853Due2025Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0853Due2025Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0000Due2025Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0000Due2025Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes0000Due2025Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes3.65Due2025Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes3.65Due2025Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes3.65Due2025Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes320Due2026Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes320Due2026Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes320Due2026Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.40Due2026Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.40Due2026Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.40Due2026Member2021-12-310000097745tmo:A1.45SeniorNotesDue2027Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:A1.45SeniorNotesDue2027Memberus-gaap:SeniorNotesMember2022-01-012022-12-310000097745tmo:A1.45SeniorNotesDue2027Memberus-gaap:SeniorNotesMember2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes175Due2027Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes175Due2027Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes175Due2027Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1054Due2027Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1054Due2027Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1054Due2027Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes48Due2027Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes48Due2027Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes48Due2027Member2021-12-310000097745tmo:SeniorNotes0.500Due2028Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes0.500Due2028Memberus-gaap:SeniorNotesMember2022-01-012022-12-310000097745tmo:SeniorNotes0.500Due2028Memberus-gaap:SeniorNotesMember2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.375Due2028Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.375Due2028Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.375Due2028Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1750Due2028Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1750Due2028Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1750Due2028Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.95Due2029Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.95Due2029Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.95Due2029Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2.60Due2029Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2.60Due2029Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2.60Due2029Member2021-12-310000097745tmo:SeniorNotes1279Due2029Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes1279Due2029Memberus-gaap:SeniorNotesMember2022-01-012022-12-310000097745tmo:SeniorNotes1279Due2029Memberus-gaap:SeniorNotesMember2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes080Due2030Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes080Due2030Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes080Due2030Member2021-12-310000097745tmo:SeniorNotes0.875Due2031Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes0.875Due2031Memberus-gaap:SeniorNotesMember2022-01-012022-12-310000097745tmo:SeniorNotes0.875Due2031Memberus-gaap:SeniorNotesMember2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2000Due2031Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2000Due2031Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2000Due2031Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2375Due2032Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2375Due2032Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2375Due2032Member2021-12-310000097745tmo:SeniorNotes149Due2032Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes149Due2032Memberus-gaap:SeniorNotesMember2022-01-012022-12-310000097745tmo:SeniorNotes149Due2032Memberus-gaap:SeniorNotesMember2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes495Due2032Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes495Due2032Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes495Due2032Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1125Due2033Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1125Due2033Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1125Due2033Member2021-12-310000097745tmo:SeniorNotes365Due2034Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes365Due2034Memberus-gaap:SeniorNotesMember2022-01-012022-12-310000097745tmo:SeniorNotes365Due2034Memberus-gaap:SeniorNotesMember2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2.875Due2037Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2.875Due2037Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2.875Due2037Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.500Due2039Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.500Due2039Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.500Due2039Member2021-12-310000097745tmo:SeniorNotes2800Due2041Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes2800Due2041Memberus-gaap:SeniorNotesMember2022-01-012022-12-310000097745tmo:SeniorNotes2800Due2041Memberus-gaap:SeniorNotesMember2021-12-310000097745tmo:SeniorNotes1625Due2041Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes1625Due2041Memberus-gaap:SeniorNotesMember2022-01-012022-12-310000097745tmo:SeniorNotes1625Due2041Memberus-gaap:SeniorNotesMember2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2069Due2042Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2069Due2042Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2069Due2042Member2021-12-310000097745tmo:SeniorNotes530Due2044Memberus-gaap:SeniorNotesMember2022-12-310000097745tmo:SeniorNotes530Due2044Memberus-gaap:SeniorNotesMember2022-01-012022-12-310000097745tmo:SeniorNotes530Due2044Memberus-gaap:SeniorNotesMember2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes4.10Due2047Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes4.10Due2047Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes4.10Due2047Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.875Due2049Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.875Due2049Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes1.875Due2049Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes200Due2051Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes200Due2051Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes200Due2051Member2021-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2382Due2052Member2022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2382Due2052Member2022-01-012022-12-310000097745us-gaap:SeniorNotesMembertmo:SeniorNotes2382Due2052Member2021-12-310000097745tmo:OtherDebtMember2022-12-310000097745tmo:OtherDebtMember2021-12-310000097745us-gaap:RevolvingCreditFacilityMember2022-12-310000097745us-gaap:RevolvingCreditFacilityMember2022-01-012022-12-310000097745us-gaap:CommercialPaperMembertmo:U.S.CommercialPaperProgramMember2022-01-012022-12-310000097745us-gaap:CommercialPaperMembertmo:EuroCommercialPaperProgramMember2022-01-012022-12-310000097745us-gaap:CommercialPaperMember2022-12-310000097745us-gaap:SeniorNotesMember2022-01-012022-12-310000097745us-gaap:InterestRateSwapMember2022-01-012022-12-31tmo:lease0000097745us-gaap:GuaranteeTypeOtherMember2022-12-310000097745tmo:AnalyticalInstrumentsMemberus-gaap:InventoriesMemberus-gaap:CostOfSalesMember2020-01-012020-12-310000097745us-gaap:StandbyLettersOfCreditMember2022-12-310000097745tmo:SuretyBondsAndOtherGuaranteesMember2022-12-310000097745us-gaap:FinancialGuaranteeMembertmo:BusinessesSoldMember2022-12-310000097745srt:MinimumMembertmo:ProductLiabilityWorkersCompensationandOtherPersonalInjuryMattersMember2022-12-310000097745srt:MaximumMembertmo:ProductLiabilityWorkersCompensationandOtherPersonalInjuryMattersMember2022-12-310000097745tmo:ProductLiabilityWorkersCompensationandOtherPersonalInjuryMattersMember2022-12-310000097745us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000097745us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000097745us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310000097745us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-12-310000097745us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-12-310000097745us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-12-310000097745us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000097745us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000097745us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000097745us-gaap:SubsequentEventMember2023-01-012023-02-230000097745us-gaap:FairValueMeasurementsRecurringMember2022-12-310000097745us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000097745us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000097745us-gaap:FairValueMeasurementsRecurringMember2021-12-310000097745us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000097745us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000097745us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000097745tmo:ContingentConsiderationMember2021-12-310000097745tmo:ContingentConsiderationMember2020-12-310000097745tmo:ContingentConsiderationMember2022-01-012022-12-310000097745tmo:ContingentConsiderationMember2021-01-012021-12-310000097745tmo:ContingentConsiderationMember2022-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2022-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2021-12-310000097745us-gaap:ForeignExchangeContractMember2022-12-310000097745us-gaap:ForeignExchangeContractMember2021-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000097745us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2022-12-310000097745us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueHedgingMemberus-gaap:OtherExpenseMember2022-01-012022-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueHedgingMemberus-gaap:OtherExpenseMember2021-01-012021-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueHedgingMember2022-01-012022-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueHedgingMember2021-01-012021-12-310000097745us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:OtherExpenseMember2022-01-012022-12-310000097745us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:OtherExpenseMember2021-01-012021-12-310000097745us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMember2022-01-012022-12-310000097745us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMember2021-01-012021-12-310000097745us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:OtherExpenseMemberus-gaap:CashFlowHedgingMember2022-01-012022-12-310000097745us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:OtherExpenseMemberus-gaap:CashFlowHedgingMember2021-01-012021-12-310000097745tmo:ForeigncurrencydenominateddebtMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2022-01-012022-12-310000097745tmo:ForeigncurrencydenominateddebtMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2021-01-012021-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2022-01-012022-12-310000097745us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2021-01-012021-12-310000097745us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2022-01-012022-12-310000097745us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-01-012021-12-310000097745us-gaap:ForeignExchangeContractMemberus-gaap:OtherExpenseMemberus-gaap:NondesignatedMember2022-01-012022-12-310000097745us-gaap:ForeignExchangeContractMemberus-gaap:OtherExpenseMemberus-gaap:NondesignatedMember2021-01-012021-12-310000097745us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2020-01-012020-12-310000097745us-gaap:InterestRateSwapMemberus-gaap:OtherExpenseMemberus-gaap:CashFlowHedgingMember2021-01-012021-12-310000097745us-gaap:SeniorNotesMember2022-12-310000097745us-gaap:SeniorNotesMember2021-12-310000097745srt:ScenarioForecastMember2023-02-230000097745us-gaap:CorporateMember2022-01-012022-12-310000097745us-gaap:CorporateMember2021-01-012021-12-310000097745us-gaap:CorporateMember2020-01-012020-12-31

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2022 or
☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Commission file number 1-8002
THERMO FISHER SCIENTIFIC INC.
(Exact name of Registrant as specified in its charter)
Delaware 04-2209186
(State of incorporation) (I.R.S. Employer Identification No.)
168 Third Avenue
Waltham, Massachusetts 02451
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (781) 622-1000
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $1.00 par value TMO New York Stock Exchange
0.750% Notes due 2024 TMO 24A New York Stock Exchange
0.125% Notes due 2025 TMO 25B New York Stock Exchange
2.000% Notes due 2025 TMO 25 New York Stock Exchange
3.200% Notes due 2026 TMO 26B New York Stock Exchange
1.400% Notes due 2026 TMO 26A New York Stock Exchange
1.450% Notes due 2027 TMO 27 New York Stock Exchange
1.750% Notes due 2027 TMO 27B New York Stock Exchange
0.500% Notes due 2028 TMO 28A New York Stock Exchange
1.375% Notes due 2028 TMO 28 New York Stock Exchange
1.950% Notes due 2029 TMO 29 New York Stock Exchange
0.875% Notes due 2031 TMO 31 New York Stock Exchange
2.375% Notes due 2032 TMO 32 New York Stock Exchange
3.650% Notes due 2034 TMO 34 New York Stock Exchange
2.875% Notes due 2037 TMO 37 New York Stock Exchange
1.500% Notes due 2039 TMO 39 New York Stock Exchange
1.875% Notes due 2049 TMO 49 New York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act:  None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒  No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐  No ☒ 
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months. Yes ☒  No ☐
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.      Large accelerated filer ☒             Accelerated filer ☐             Non-accelerated filer ☐ Smaller reporting company ☐        Emerging growth company ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐  No ☒
As of July 1, 2022, the aggregate market value of the voting stock held by nonaffiliates of the Registrant was approximately $214,582,365,000 (based on the last reported sale of common stock on the New York Stock Exchange Composite Tape reporting system on July 1, 2022).
As of February 4, 2023, the Registrant had 385,430,077 shares of Common Stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Sections of Thermo Fisher’s definitive Proxy Statement for the 2023 Annual Meeting of Shareholders are incorporated by reference into Parts II and III of this report.


THERMO FISHER SCIENTIFIC INC.
ANNUAL REPORT ON FORM 10-K
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022
TABLE OF CONTENTS
Page
PART I
3
PART II
PART III
PART IV

2

THERMO FISHER SCIENTIFIC INC.
PART I

Forward-looking Statements
Forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934 (the Exchange Act), are made throughout this Annual Report on Form 10-K. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements, including without limitation statements regarding: projections of revenues, expenses, earnings, margins, tax rates, tax provisions, cash flows, pension and benefit obligations and funding requirements, and our liquidity position; cost reductions, restructuring activities, new product and service developments, competitive strengths or market position, acquisitions or divestitures; growth, declines and other trends in markets we sell into; new or modified laws, regulations and accounting pronouncements; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; foreign currency exchange rates and fluctuations in those rates; general economic and capital markets conditions; the timing of any of the foregoing; assumptions underlying any of the foregoing; the expected impact of the COVID-19 pandemic on the company’s business; and any other statements that address events or developments that Thermo Fisher intends or believes will or may occur in the future. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words. While the company may elect to update forward-looking statements in the future, it specifically disclaims any obligation to do so, even if the company’s estimates change, and readers should not rely on those forward-looking statements as representing the company’s views as of any date subsequent to the date of the filing of this report. A number of important factors could cause the results of the company to differ materially from those indicated by such forward-looking statements, including those detailed under the heading, “Risk Factors” in Part I, Item 1A.
Item 1.    Business
Description of Business
Thermo Fisher Scientific Inc. (also referred to in this document as “Thermo Fisher,” “we,” the “company,” or the “registrant”) is the world leader in serving science. Our Mission is to enable our customers to make the world healthier, cleaner and safer. We serve customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial, research and development, quality and process control settings. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
We continuously increase our depth of capabilities across our broad portfolio of innovative products and services and leverage our extensive global channels to address our customers’ needs. We do this through organic investments in research and development, capacity, and through acquisitions. Our goal is to enable our customers to be more productive in an increasingly competitive business environment and enabling them to advance their important work.
Business Segments and Products
We report our business in four segments – Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
Life Sciences Solutions Segment
Through our Life Sciences Solutions segment, we provide an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. These products and services are used by customers in pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Life Sciences Solutions includes four primary businesses – Biosciences, Genetic Sciences, Clinical Next-Generation Sequencing, and BioProduction.
Our biosciences business includes reagents, instruments and consumables that help our customers conduct biological and medical research in areas such as molecular biology and protein biology, discover new drugs and vaccines, and diagnose infection and disease. Our genetic sciences business combines a wide variety of instruments and related reagents used to provide high-value genomic solutions to assist customer decisions in the research, clinical, healthcare and applied markets. Our clinical next-generation sequencing (NGS) business focuses on delivering simple, fast and cost-effective NGS technology for a range of applications with a particular focus on oncology. Our bioproduction business supports developers and manufacturers of biological-based therapeutics and vaccines with a portfolio of premium solutions and services focused on upstream cell
3

THERMO FISHER SCIENTIFIC INC.
culture, downstream purification, analytics for detection and quantitation of process/product impurities, and a suite of single-use solutions spanning the biologics workflow.
Analytical Instruments Segment
Through our Analytical Instruments segment, we provide a broad offering of instruments and the supporting consumables, software and services that are used for a range of applications. These products and services are used by customers in pharmaceutical, biotechnology, academic, government, environmental and other research and industrial markets, as well as the clinical laboratory. This segment includes three primary businesses – Chromatography and Mass Spectrometry, Chemical Analysis, and Electron Microscopy.
Our chromatography and mass spectrometry business develops and provides analytical instrumentation for organic and inorganic sample analysis across both applied technologies and scientific research. Our chemical analysis products fall into three main categories: production, process and analytics; field and safety instruments; and environmental and process instruments. Our electron microscopy business serves customers in the life sciences, materials science, and semiconductor markets providing integrated workflows that power research development and production solutions.
Specialty Diagnostics Segment
Our Specialty Diagnostics segment offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. Our healthcare products are used to increase the speed and accuracy of diagnoses, which improves patient care in a more cost-efficient manner. This segment has five primary businesses – Clinical Diagnostics, ImmunoDiagnostics, Microbiology, Transplant Diagnostics and our Healthcare Market Channel.
Our clinical diagnostics products include a broad offering of liquid, ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls and calibration verification fluids. Such products are used for, among other things, drugs-of-abuse testing, therapeutic drug monitoring, thyroid hormone testing, serum toxicity, first trimester screening, and tumor markers testing. Our immunodiagnostics offerings include developing, manufacturing and marketing complete blood-test systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases. Our microbiology offerings include dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products and associated products for the microbiology laboratory. Our transplant diagnostics products include human leukocyte antigen (HLA) typing and testing for the organ transplant market. Our healthcare market channel offerings include a broad array of consumables, diagnostic kits and reagents, equipment, instruments, solutions and services for hospitals, clinical laboratories, reference laboratories, physicians’ offices and other clinical testing facilities.
Laboratory Products and Biopharma Services Segment
Our Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. Our unique combination of self-manufactured and sourced products and extensive service offering enables our customers to focus on their core activities and helps them to be more efficient, productive and cost-effective. The segment also includes a comprehensive offering of outsourced services used by the pharmaceutical and biotech industries for drug development, clinical research, clinical trials services and commercial drug manufacturing. We serve the pharmaceutical, biotechnology, academic, medical device, government and other research and industrial markets, as well as the clinical laboratory market through five key businesses: Laboratory Products, Laboratory Chemicals, Research and Safety Market Channel, Pharma Services and Clinical Research.
Our laboratory products are used for life science research and drug discovery and development to advance the prevention and cure of diseases and enhance quality of life. Our laboratory chemicals offering comprises a broad range of chemicals, solvents and reagents supporting virtually every laboratory application – from research and drug discovery to development and manufacturing. Our research and safety market channel offers a mix of products that are manufactured by Thermo Fisher, by third parties for us on a private-label basis, and by third parties under their brands but offered for sale through us. Our pharma services business provides the entire spectrum of development, manufacturing and clinical trials services for both small-molecule and large-molecule pharmaceuticals. Our clinical research business offers comprehensive, integrated clinical development and analytical services including all phases of development (i.e., Phases I-IV), peri- and post-approval and site and patient access services.
During 2022, the Life Sciences Solutions and Specialty Diagnostics segments as well as the laboratory products business continued to support COVID-19 diagnostic testing, scaling and evolving their molecular diagnostics solutions and plastic consumables businesses to respond to the on-going COVID-19 pandemic. The biosciences, bioproduction and laboratory equipment and consumables businesses also leveraged their capacity to meet the needs of pharma and biotech customers as they
4

THERMO FISHER SCIENTIFIC INC.
rapidly expanded their own production volumes to meet global vaccine manufacturing requirements. Additionally, through our pharma services business, we provided our pharma and biotech customers with the services they needed to develop and produce vaccines and therapies globally.
Sales and Marketing
We market and sell our products and services through a direct sales force, customer-service professionals, electronic commerce and third-party distributors. Our global team delivers a combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
We have approximately 15,000 sales personnel including highly trained technical specialists who enable us to better meet the needs of our more technical end-users. We also provide customers with product standardization and other supply-chain-management services to reduce procurement costs.
New Products and Research and Development
Our business includes the development and introduction of new products and may include entry into new business segments. We anticipate that we will continue to make significant expenditures for research and development as we seek to provide a continuing flow of innovative products to maintain and improve our competitive position.
Resources
Raw Materials
Our management team believes that we have a readily available supply of raw materials for all of our significant products from various sources. No single supplier is material, although for reasons of quality assurance, regulatory requirements, cost effectiveness, availability or uniqueness of design, certain materials components may be sourced from a single supplier or a limited number of suppliers that can readily provide such materials or components.
Raw material and fuel prices are subject to fluctuations due to market conditions. We employ many strategies, including the use of alternative materials, to mitigate the effect of these fluctuations on our results.
Patents, Licenses and Trademarks
Patents are important in many aspects of our business. No particular patent, or related group of patents, is so important, however, that its loss would significantly affect our operations as a whole. Where appropriate, we seek patent protection for inventions and developments made by our personnel that are incorporated into our products or otherwise fall within our fields of interest. Patent rights resulting from work sponsored by outside parties do not always accrue exclusively to the company and may be limited by agreements or contracts.
We protect some of our technology as trade secrets and, where appropriate, we use trademarks or register trademarks used in connection with products. We also enter into license agreements with others to grant and/or receive rights to intellectual property rights.
All trademarks, trade names, product names, graphics and logos of Thermo Fisher contained herein are trademarks or registered trademarks of Thermo Fisher or its subsidiaries, as applicable, in the United States and/or other countries. Solely for convenience, we may refer to trademarks in this Annual Report on Form 10-K without the ™ and ® symbols. Such references are not intended to indicate, in any way, that we will not assert, to the fullest extent permitted by law, our rights to our trademarks. To the extent other trademarks appear in this Annual Report on Form 10-K, they are the property of their respective owners.
Seasonal Influences
Revenues in the fourth quarter are historically stronger than in other quarters due to the capital spending patterns of industrial, pharmaceutical and government customers. Sales of seasonal products, such as COVID-19, allergy and flu tests and related diagnostic products, vary quarter to quarter and year to year.
Competition
The company encounters aggressive and able competition in virtually all of the markets we serve. Because of the diversity of our products and services, we face many different types of competitors and competition. Our competitors include a broad range of manufacturers, third-party distributors and service providers. Competitive climates in many of the markets we serve are characterized by changing technology and customer demands that require continuing research and development. Our success primarily depends on the following factors:
5

THERMO FISHER SCIENTIFIC INC.
•technical performance and advances in technology that result in new products and improved price/performance ratios;
•product differentiation, availability and reliability;
•the depth of our capabilities;
•our reputation among customers as a quality provider of products and services;
•customer service and support;
•active research and application-development programs; and
•relative prices of our products and services.
Government Regulation
Environmental Regulations
We are subject to various laws and governmental regulations concerning environmental matters and employee safety and health in the United States and other countries. U.S. federal environmental legislation that affects us includes the Toxic Substances Control Act, the Resource Conservation and Recovery Act, the Clean Air Act, the Clean Water Act, the Safe Drinking Water Act, and the Comprehensive Environmental Response Compensation and Liability Act (CERCLA). We are also subject to regulation by the Occupational Safety and Health Administration (OSHA) concerning employee safety and health matters. The United States Environmental Protection Agency (USEPA), OSHA, and other federal agencies have the authority to promulgate regulations that have an effect on our operations.
In addition to these federal laws and regulations, various states have been delegated certain authority under the aforementioned federal statutes and have authority over these matters under state laws. Many state and local governments have adopted environmental and employee safety and health laws and regulations, some of which are similar to federal requirements.
A number of our operations involve the handling, manufacturing, use or sale of substances that are or could be classified as toxic or hazardous materials within the meaning of applicable laws. Consequently, some risk of environmental harm is inherent in our operations and products, as it is with other companies engaged in similar businesses.
Our expenses for environmental requirements are incurred generally for ongoing compliance and historical remediation matters. Based on current information, we believe that these compliance costs are not material. For historical remediation obligations, our expenditures relate primarily to the cost of permitting, installing, and operating and maintaining groundwater-treatment systems and other remedial measures.
Our Fair Lawn and Somerville, New Jersey facilities entered into administrative consent orders with the New Jersey Department of Environmental Protection in 1984 to maintain groundwater-remediation activities at these sites, and are currently under the State’s Licensed Site Remediation Professional Program. As the owner of the Fair Lawn facility, we are listed as a potentially responsible party for remediation within an area called the Fair Lawn Wellfields Superfund Site, and, in 2008, the company and certain other parties entered into a consent order with the USEPA to complete a Remedial Investigation/Feasibility Study. In 2018, the USEPA issued a Record of Decision, setting forth the scope of required remediation work at the site, which includes upgrading a water treatment plant to address constituents such as chlorinated organic compounds, 1,4-dioxane, and perfluorooctanoic acid/perfluorooctane sulfonate (PFOA/PFOS). In 2020, the court approved a consent decree that requires the company and another responsible party to finance and perform the required remediation work with USEPA oversight, which has been ongoing and is pending USEPA’s approval of the water treatment plant design.
In 2011, our Life Technologies subsidiary entered into a consent decree with the USEPA and other responsible parties to implement a groundwater remedy at the former Davis Landfill Superfund site in Smithfield, Rhode Island. After years of additional study, in September, 2020, USEPA revised its cleanup plan by selecting an interim remedial approach that includes groundwater treatment followed by additional monitoring of site conditions. Depending on the results of these treatment and monitoring activities over the next several years, USEPA anticipates selecting a final groundwater remedy for the site. In November 2021, the 2011 consent decree was amended to reflect the parties’ obligations to implement USEPA’s interim remedy, for which pre-design work commenced during 2022.
We record accruals for environmental liabilities based on current interpretations of environmental laws and regulations when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. We calculate estimates based upon several factors, including reports prepared by environmental specialists and management’s knowledge and experience with these environmental matters. We include in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites. Accrued liabilities for environmental matters totaled $75 million at December 31, 2022.
These environmental liabilities do not include third-party recoveries to which we may be entitled. We believe that our accrual is adequate for the environmental liabilities we currently expect to incur. As a result we believe that our ultimate
6

THERMO FISHER SCIENTIFIC INC.
liability with respect to environmental matters will not have a material adverse effect on our financial position, results of operations or cash flows. However, we may be subject to remedial or compliance costs due to future events, such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies, changes in the conduct of our operations, and the effect of changes in accounting rules, which could have a material adverse effect on our financial position, results of operations or cash flows. For a discussion of the environmental laws and regulations that the Company’s operations, products and services are subject to and other environmental contingencies, refer to Note 12 to our Consolidated Financial Statements.
Other Laws and Regulations
Our operations, and some of the products and services we offer, are subject to a number of complex and stringent laws and regulations governing the development, testing, approval, production, handling, transportation and distribution of chemicals, drugs and other similar products, including the operating and security standards of the Food and Drug Administration, the Drug Enforcement Administration, the Bureau of Alcohol, Tobacco, Firearms and Explosives, and various state boards of pharmacy as well as comparable state and foreign agencies. As Thermo Fisher’s businesses also include export and import activities, we are subject to pertinent laws enforced by the U.S. Departments of Commerce, State and Treasury. In addition, our logistics activities must comply with the rules and regulations of the Department of Transportation, the Federal Aviation Administration and similar foreign agencies. While we believe we are in compliance in all material respects with such laws and regulations, any noncompliance could result in substantial fines or otherwise restrict our ability to provide competitive distribution services and thereby have an adverse effect on our financial condition. To date, no such laws or regulations have had a material impact on our operations.
We are subject to laws and regulations governing government contracts, and failure to address these laws and regulations or comply with government contracts could harm our business by leading to a reduction in revenues associated with these customers. We have agreements relating to the sale of our products to government entities and, as a result, we are subject to various statutes and regulations that apply to companies doing business with the government. We are also subject to investigation for compliance with the regulations governing government contracts. A failure to comply with these regulations could also result in suspension of these contracts, criminal, civil and administrative penalties or debarment.
For a discussion of risks related to changes in governmental regulations, refer to “Risk Factors” in Part I, Item 1A.
Human Capital
The success of Thermo Fisher is fueled by colleagues who are highly engaged and feel empowered to achieve their goals. Everything we do starts with our Mission – to enable our customers to make the world healthier, cleaner and safer. Our colleagues understand the role they play in fulfilling that Mission and that inspires them to bring their best to work each day. Our Mission is not only a differentiator for us externally, but a motivator for us internally.
Our culture is rooted in our 4i Values of Integrity, Intensity, Innovation and Involvement. Within this framework, we strive to create a safe, fair and positive working environment for our colleagues around the world. We want our teams to feel they have a stake in our success, a voice in our direction and to be empowered to make a difference for the key stakeholders we serve.
Every year, we conduct an Employee Involvement Survey to solicit direct feedback from our colleagues on what we’re doing well and where we need to improve. We then compile the feedback to measure our progress using three key indices: Leadership, Involvement and Inclusion. Our continued focus on enhancing our culture helps position our company to be an even better place to work.
We are committed to maintaining the strongest team in our industry, focusing on developing and retaining our colleagues, while leveraging our leadership to attract new colleagues to our company. As of December 31, 2022, we employed approximately 130,000 colleagues globally, with an approximate regional distribution as follows: 67,000 based in the Americas, 21,000 in the Asia Pacific region, and nearly 42,000 in Europe, the Middle East and Africa (EMEA).
Diversity and Inclusion
We recognize that the future aspirations outlined in our Vision for 2030, which serves as our long-term roadmap, will only be achievable if we have a culture that values diversity and inclusion. While diversity of gender and ethnicity are important – and we’re focused on continuously improving– for us, diversity of backgrounds, experiences and viewpoints is equally vital to our long-term success. When those differences are welcomed and supported, we create an inclusive workplace that unlocks the true benefits of diversity.
Diversity and Inclusion (D&I) is not an initiative at Thermo Fisher. It’s woven into the fabric of our culture, and our colleagues are encouraged to openly share the wide range of perspectives they represent. We work together to create an
7

THERMO FISHER SCIENTIFIC INC.
inclusive culture where our colleagues feel they belong and are empowered to contribute, collaborate and innovate. Embracing individual differences is critical to our success. For example, Thermo Fisher was named as a Top Female Friendly Company, Best Employer for Women, and Best Employer for Veterans by Forbes in 2022, Best Place to Work for Disability Inclusion, as well as a Best Place to Work for LGBTQ Equality for the seventh consecutive year. Establishing this kind of environment is critical in empowering our colleagues so they can contribute their best ideas and bring their true selves to work each day.
Our D&I focus is embedded in every stage of our colleague lifecycle – from recruiting to onboarding, training, development and longer-term career planning. We track our progress on our D&I strategic objectives through a core set of metrics that are reviewed during routine business operating mechanisms, including Quarterly Business Reviews, Human Resource Reviews, Board Reviews and through team dashboards that are shared each month with leaders across the company. This enables frequent, meaningful, data-driven discussions across our businesses and functions on a range of D&I factors, including gender and ethnic representation. This approach also ensures we consistently prioritize our opportunities to improve. We understand the critical role diversity plays in sustained business success, and our teams are empowered to ensure our workforce represents the customers we serve. Further, to provide additional transparency to our U.S. workforce demographics, following our report submission to the U.S. Equal Employment Opportunity Commission, we disclose our EEO-1 report on our website each year.
We are committed to ensuring our colleagues have access to resources, awareness training and internal networks that offer support and guidance. Our D&I strategy is greatly enabled by our Business Resource Groups (BRGs), which bring together individuals with similar interests to share experiences, learn from each other and collaborate to identify solutions to business challenges. Our BRGs reinforce that all colleagues can make a difference for our customers, for each other and for our company. As of December 31, 2022, we had 9 global BRGs, with more than 230 local BRG chapters.
Talent Development
Our overarching goal from a talent perspective is to create opportunities for our colleagues to achieve their full potential and career aspirations here at Thermo Fisher. We focus on the entire lifecycle of a colleague’s career, from their initial recruitment, to onboarding, through ongoing development and training to enhance their skills so they are in the best position to deliver on their goals and achieve their career aspirations.
In today’s environment, we know talent is a key competitive advantage, and that building the strongest team in the industry is critical to our future. From our colleague referral program, summer internships, university relations, to our Graduate Leadership Development Program, we continue to build strong internal and external sourcing channels.
Once on board, talent development at Thermo Fisher is a key organizational capability. We continue to make significant investments to support our colleagues along every step of their career journey to help support their success. Our talent development framework incorporates a multi-faceted approach, including formal and self-paced training, networking opportunities, on-the-job stretch learning, coaching, mentoring and manager training utilizing contemporary technology solutions to support the broad needs of our workforce.
We provide multiple programs at all career levels, from online learning for all colleagues through Thermo Fisher University, to focused trainings for managers at various experience levels, to our Global Leadership Program for executives. We also support our colleagues’ career advancement through our tuition reimbursement program.
In a company our size, we can also actively manage our talent through rotational opportunities across our businesses, functions and geographies that help our colleagues gain new experiences, share knowledge and broaden their skills. Our executives and leaders participate in frequent talent discussions as well as formal reviews, leveraging workforce data and predictive analytics to better anticipate the talent requirements of our business based on our growth opportunities and market demand.
Thermo Fisher is dedicated to talent development to meet our evolving business needs and to provide our colleagues with opportunities for long and fulfilling careers. Our colleagues are passionate about our company, and their role in our success, and it’s our responsibility to help them reach their full potential.
Total Rewards
We offer a comprehensive total rewards package that we regularly evaluate and measure against established benchmarks to ensure its effectiveness in recruiting and retention, and to position Thermo Fisher as an employer of choice. In 2022, we reinvested approximately $350 million of additional compensation payments to our colleagues to help them with the temporary impacts of high inflation.
Our health and wellness programs provide competitive, flexible programs that our global colleagues and their families can count on. For example, for U.S. colleagues, we offer a choice of comprehensive national medical, dental and vision plans; a
8

THERMO FISHER SCIENTIFIC INC.
wellness program, including valuable health incentive opportunities and tax-advantaged savings and spending accounts; as well as commuter benefits, employee assistance programs, optional group legal coverage, and company-paid disability, accident and life insurance. We also offer a company-paid proprietary program for cancer care called the Impact Program, which gives our colleagues and their families access to personalized support and direct lines of communication to experts in cancer genetics and genomics. Similar benefits are available in all countries around the world where we operate.
We also invest in our colleagues’ financial health, helping them to grow and protect their savings, plan for the future and share in the success of the company they are helping to build. We deliver comprehensive rewards, including competitive base pay, and also provide a variety of incentive and equity programs that, by design, directly link the impact of colleague contributions to the company’s overall success.
Disclosure Pursuant to Section 13(r) of the Exchange Act
The Russian Federal Security Service (the FSB) is designated as a blocked party under Executive Order 13382. While we have paused sales and manufacturing operations in Russia and Belarus, in the normal course of business, as authorized by General License 1B issued by the U.S. Department of the Treasury’s Office of Foreign Assets Control, our Russian affiliate responds to regulatory inquiries from the FSB and otherwise engages with the FSB as a licensing authority. These interactions did not result in any revenue or otherwise contribute to our net income for the quarter. Our Russian affiliate may respond to similar regulatory inquiries and otherwise continue to engage with the FSB as a licensing authority in the future, as necessary and to the extent permitted by applicable U.S. sanctions laws and regulations.
Available Information
The company files annual, quarterly and current reports, proxy statements and other documents with the Securities and Exchange Commission (SEC) under the Exchange Act. The SEC maintains a website that contains reports, proxy and information statements and other information that issuers, including the company, file electronically with the SEC. The public can obtain any documents that we file with the SEC at www.sec.gov. We also make available free of charge on or through our own website at www.thermofisher.com our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and, if applicable, amendments to those reports filed or furnished pursuant to Section 13(a) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. In addition, paper copies of these documents may be obtained free of charge by writing to the company care of its Investor Relations Department at our principal executive office located at 168 Third Avenue, Waltham, Massachusetts 02451.
Information about Our Executive Officers
As of February 23, 2023, our executive officers were:
Name Age Present Title
(Fiscal Year First Became Executive Officer)		 Other Positions Held
Marc N. Casper 54 Chairman, President and Chief Executive Officer (2001) President and Chief Executive Officer (2009-2020)
Chief Operating Officer (2008-2009)
Executive Vice President (2006-2009)
Michel Lagarde 49 Executive Vice President and Chief Operating Officer (2017) Executive Vice President (2019-2021)
Senior Vice President and President, Pharma Services (2017-2019)
President and Chief Operating Officer, Patheon N.V. (2016-2017)
Managing Director, JLL Partners (2008-2016)
Gianluca Pettiti 44 Executive Vice President (2021) Senior Vice President and President, Specialty Diagnostics (2019-2021)
President, Biosciences (2018-2019)
President, China (2015-2017)
Michael A. Boxer 61 Senior Vice President and General Counsel (2018) Senior Vice President, General Counsel and Secretary (2021-2022)
Executive Vice President and Group General Counsel, Luxottica Group S.p.A. (2011-2017)
Stephen Williamson 56 Senior Vice President and Chief Financial Officer (2015) Vice President, Financial Operations (2008-2015)
Joseph R. Holmes 44 Vice President and Chief Accounting Officer (2021) Senior Director, Technical Accounting (2017-2021)
9

THERMO FISHER SCIENTIFIC INC.
Item 1A.    Risk Factors
Set forth below are the risks that we believe are material to our investors. This section contains forward-looking statements. You should refer to the explanation of the qualifications and limitations on forward-looking statements in Item 1. Business under the caption “Forward-looking Statements”.
Industry and Economic Risks
Our growth would suffer if the markets into which we sell our products and services decline, do not grow as anticipated or experience cyclicality. Our growth depends in part on the growth of the markets which we serve. Any decline or lower than expected growth in our served markets would diminish demand for our products and services, which would adversely affect our financial statements. Certain of our businesses operate in industries that may experience periodic, cyclical downturns.
Our business is affected by general economic conditions and related uncertainties affecting markets in which we operate. Our business is affected by general economic conditions, both inside and outside the U.S. Both domestic and international markets experienced significant inflationary pressures in 2022 and inflation rates in the U.S., as well as in other countries in which we operate, continue at elevated levels for the near-term. If the global economy and financial markets, or economic conditions in Europe, the U.S. or other key markets, continue to be unstable, they could adversely affect the business, results of operations and financial condition of the company and its customers, distributors, and suppliers, having the effect of:
•reducing demand for some of our products;
•increasing the rate of order cancellations or delays;
•increasing the risk of excess and obsolete inventories;
•increasing pressure on the prices for our products and services;
•causing supply interruptions, which could disrupt our ability to produce our products; and
•creating longer sales cycles, and greater difficulty in collecting sales proceeds and slower adoption of new technologies.
Economic, political, foreign currency and other risks associated with international sales and operations could adversely affect our results of operations. International markets contribute a substantial portion of our revenues, and we intend to continue expanding our presence in these regions. The exposure to fluctuations in currency exchange rates takes on different forms. International revenues and costs are subject to the risk that fluctuations in exchange rates could adversely affect our reported revenues and profitability when translated into U.S. dollars for financial reporting purposes. These fluctuations could also adversely affect the demand for products and services provided by us. As a multinational corporation, our businesses occasionally invoice third-party customers in currencies other than the one in which they primarily do business (which we refer to as the functional currency). Movements in the invoiced currency relative to the functional currency could adversely impact our cash flows and our results of operations. As our international sales grow, exposure to fluctuations in currency exchange rates could have a larger effect on our financial results. In 2022, currency translation had an unfavorable effect of $1.35 billion on revenues due to the strengthening of the U.S. dollar relative to other currencies in which the company sells products and services.
Some emerging market countries may be particularly vulnerable to periods of global and local political, legal, regulatory and financial instability, including issues of geopolitical relations, the imposition of international sanctions in response to certain state actions and/or sovereign debt issues, and may have a higher incidence of corruption and fraudulent business practices. As a result of these and other factors, our strategy to grow in emerging markets may not be successful, and growth rates in these markets may not be sustainable.
In addition, many of our employees, contract manufacturers, suppliers, job functions, outsourcing activities and manufacturing facilities are located outside the U.S. Accordingly, our future results could be harmed by a variety of factors, including:
•interruption to transportation flows for delivery of parts to us and finished goods to our customers;
•changes in a specific country's or region's political, economic or other conditions;
•changes in diplomatic and trade relationships, including new tariffs, trade protection measures, import or export licensing requirements, trade embargoes and sanctions and other trade barriers;
10

THERMO FISHER SCIENTIFIC INC.

•tariffs imposed by the U.S. on goods from other countries and tariffs imposed by other countries on U.S. goods, including the tariffs adopted by the U.S. government on various imports from China and by the Chinese government on certain U.S. goods;
•the impact of public health epidemics/pandemics on the global economy, such as the COVID-19 pandemic;
•uncertainties regarding the collectability of accounts receivable;
•the imposition of governmental controls;
•diverse data privacy and protection requirements;
•supply interruptions, which could disrupt our ability to produce our products;
•increases in materials, energy, labor or other manufacturing-related costs or higher supply chain logistics costs;
•negative consequences from changes in tax laws;
•difficulty in staffing and managing widespread operations;
•differing labor regulations;
•differing protection of intellectual property;
•unexpected changes in regulatory requirements; and
•geopolitical uncertainty or turmoil, including terrorism and war.
Demand for some of our products depends on capital spending policies of our customers and on government funding policies. Our customers include pharmaceutical and chemical companies, laboratories, universities, healthcare providers, government agencies and public and private research institutions. Many factors, including public policy spending priorities, available resources, and product and economic cycles, have a significant effect on the capital spending policies of these entities. Spending by some of these customers fluctuates based on budget allocations and the timely passage of the annual federal budget. An impasse in federal government budget decisions could lead to substantial delays or reductions in federal spending.
We are subject to risks associated with public health epidemics and pandemics, such as the ongoing COVID-19 pandemic. Our global operations expose us to risks associated with public health epidemics and pandemics. COVID-19 has had an adverse impact on certain of our operations, supply chains and distribution systems, and we may experience unpredictable reductions in supply and demand for certain of our products and services. National, state and local governments have implemented and may continue to implement safety precautions, including quarantines, border closures, increased border controls, travel restrictions, shelter in place orders and shutdowns and other measures. These measures may disrupt normal business operations and may have significant negative impacts on businesses and financial markets worldwide. Our ability to continue to manufacture products is highly dependent on our ability to maintain the safety and health of our factory employees. The ability of our employees to work may be significantly impacted by the COVID-19 pandemic or future epidemics and pandemics. In addition, the duration and extent of future revenues from sales of products related to the COVID-19 response are uncertain and dependent primarily on customer testing demand as well as therapy and vaccine demand.
Business Risks
We must develop new products, adapt to rapid and significant technological change, respond to introductions of new products by competitors and maintain quality to remain competitive. Our growth strategy includes significant investment in and expenditures for product development. We sell our products in several industries that are characterized by rapid and significant technological changes, frequent new product and service introductions and enhancements and evolving industry standards. Competitive factors include technological innovation, price, service and delivery, breadth of product line, customer support, e-business capabilities and the ability to meet the special requirements of customers. Our competitors may adapt more quickly to new technologies and changes in customers’ requirements than we can. Without the timely introduction of new products, services and enhancements, our products and services will likely become technologically obsolete over time, in which case our revenues and operating results would suffer.
Many of our existing products and those under development are technologically innovative and require significant planning, design, development and testing at the technological, safety, quality, product and manufacturing-process levels. Our customers use many of our products to develop, test and manufacture their own products. As a result, we must anticipate industry trends and develop products in advance of the commercialization of our customers’ products. If we fail to adequately develop products or predict our customers’ needs and future activities, we may invest heavily in research and development of products and services that do not lead to significant revenues.
11

THERMO FISHER SCIENTIFIC INC.

It may be difficult for us to implement our strategies for improving internal growth. Our growth depends in part on the growth of the markets which we serve. Any decline or lower than expected growth in our served markets could diminish demand for our products and services, which would adversely affect our results of operations and financial condition. To address this issue, we are pursuing a number of strategies to improve our internal growth, including:
•strengthening our presence in selected geographic markets;
•allocating research and development funding to products with higher growth prospects;
•developing new applications for our technologies;
•expanding our service offerings;
•continuing key customer initiatives;
•combining sales and marketing operations in appropriate markets to compete more effectively;
•finding new markets for our products; and
•continuing the development of commercial tools and infrastructure to increase and support cross-selling opportunities of products and services to take advantage of our depth in product offerings.
We may not be able to successfully implement these strategies, and these strategies may not result in the expected growth of our business.
Because we compete directly with certain of our larger customers and product suppliers, our results of operations could be adversely affected in the short term if these customers or suppliers abruptly discontinue or significantly modify their relationship with us. Our largest customer in the laboratory products business is also a significant competitor. Our business may be harmed in the short term if our competitive relationship in the marketplace with certain of our large customers results in a discontinuation of their purchases from us. In addition, we manufacture products that compete directly with products that we source from third-party suppliers. We also source competitive products from multiple suppliers. Our business could be adversely affected in the short term if any of our large third-party suppliers abruptly discontinues selling products to us.
Our inability to complete any pending acquisitions or to successfully integrate any new or previous acquisitions could have a material adverse effect on our business. Our business strategy includes the acquisition of technologies and businesses that complement or augment our existing products and services. Certain acquisitions may be difficult to complete for a number of reasons, including the need for antitrust and/or other regulatory approvals, as well as disputes or litigation. Any acquisition we may complete may be made at a substantial premium over the fair value of the net identifiable assets of the acquired company. Further, we may not be able to integrate acquired businesses successfully into our existing businesses, make such businesses profitable, or realize anticipated cost savings or synergies, if any, from these acquisitions, which could adversely affect our business.
Moreover, we have acquired many companies and businesses. As a result of these acquisitions, we recorded significant goodwill and indefinite-lived intangible assets (primarily tradenames) on our balance sheet, which amount to approximately $41.20 billion and $1.24 billion, respectively, as of December 31, 2022. In addition, we have definite-lived intangible assets totaling $16.21 billion as of December 31, 2022. We assess the realizability of goodwill and indefinite-lived intangible assets annually as well as whenever events or changes in circumstances indicate that these assets may be impaired. We assess the realizability of definite-lived intangible assets whenever events or changes in circumstances indicate that these assets may be impaired. These events or circumstances would generally include operating losses or a significant decline in earnings associated with the acquired business or asset. Our ability to realize the value of the goodwill and intangible assets will depend on the future cash flows of these businesses. These cash flows in turn depend in part on how well we have integrated these businesses. If we are not able to realize the value of the goodwill and intangible assets, we may be required to incur material charges relating to the impairment of those assets.
Operational Risks
Our reliance upon sole or limited sources of supply for certain materials or components could cause production interruptions, delays and inefficiencies. Some of our businesses purchase certain materials from sole or limited source suppliers for reasons of quality assurance, regulatory requirements, cost effectiveness, availability or uniqueness of design. If these or other suppliers encounter financial, operating or other difficulties, or if our relationship with them changes, we might not be able to quickly establish or qualify replacement sources of supply. The supply chains for our businesses could also be disrupted by supplier capacity constraints, bankruptcy or exiting of the business for other reasons, decreased availability or increased cost of key raw materials or commodities, such as energy, and external events such as global economic downturns and macroeconomic trends, natural disasters, pandemic health issues such as COVID-19, war, terrorist actions, governmental
12

THERMO FISHER SCIENTIFIC INC.

actions and legislative or regulatory changes. Any of these factors could result in production interruptions, delays, extended lead times and inefficiencies.
A significant disruption in, or breach in security of, our information technology systems or violation of data privacy laws could adversely affect our business. As a part of our ongoing effort to upgrade our current information systems, we periodically implement new enterprise resource planning software and other software applications to manage certain of our business operations. As we implement and add functionality, problems could arise that we have not foreseen. Such problems could disrupt our ability to provide quotes, take customer orders and otherwise run our business in a timely manner. When we upgrade or change systems, we may suffer interruptions in service, loss of data or reduced functionality. In addition, if our new systems fail to provide accurate pricing and cost data our results of operations and cash flows could be adversely affected.
We also rely on our information technology systems to process, transmit and store electronic information (including sensitive data such as confidential business information and personally identifiable data relating to employees, customers and other business partners) and to manage or support a variety of critical business processes and activities (such as interacting with suppliers, selling our products and services, fulfilling orders and billing, collecting and making payments, shipping products, providing services and support to customers, tracking customer activity, fulfilling contractual obligations and otherwise conducting business). Our systems may be vulnerable to damage or interruption from natural disasters, power loss, telecommunication failures, terrorist attacks, computer hackers, computer viruses, ransomware, phishing, computer denial-of-service attacks, unauthorized access to customer or employee data or company trade secrets, and other attempts to harm our systems. Certain of our systems are not redundant, and our disaster recovery planning is not sufficient for every eventuality. Despite any precautions we may take, such problems could result in, among other consequences, interruptions in our services, which could harm our reputation and financial results. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. Any of the cyber-attacks, breaches or other disruptions or damage described above, if significant, could materially interrupt our operations, delay production and shipments, result in theft of our and our customers’ intellectual property and trade secrets, damage customer, business partner and employee relationships and our reputation or result in defective products or services, legal claims and proceedings, liability and penalties under privacy laws and increased cost for security and remediation, each of which could adversely affect our business and financial results. Our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.
If we are unable to maintain reliable information technology systems and appropriate controls with respect to global data privacy and security requirements and prevent data breaches, we may suffer regulatory consequences in addition to business consequences. As a global organization, we are subject to data privacy and security laws, regulations, and customer-imposed controls in numerous jurisdictions as a result of having access to and processing confidential, personal and/or sensitive data in the course of our business. For example, in the U.S., individual states regulate data breach and security requirements and multiple governmental bodies assert authority over aspects of the protection of personal privacy. European laws require us to have an approved legal mechanism to transfer personal data out of Europe, and the EU General Data Protection Regulation imposes significantly stricter requirements in how we collect and process personal data. Several countries, such as China, have passed laws that require personal data relating to their citizens to be maintained on local servers and impose additional data transfer restrictions. Government enforcement actions can be costly and interrupt the regular operation of our business, and data breaches or violations of data privacy laws can result in fines, reputational damage and civil lawsuits, any of which may adversely affect our business, reputation and financial statements.
We may have difficulty attracting and retaining a highly qualified workforce. Our success is largely dependent upon our ability to attract and retain highly qualified scientific, technical, clinical and management workforce in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract them. We may face difficulty in attracting and retaining key talent for a number of reasons, including management changes or recruitment by competitors. Our ability to attract and retain key talent also depends in part on how well we maintain a strong workplace culture that is attractive to employees. Macroeconomic conditions, specifically increased competition for employees and wage inflation, could have a material impact on our ability to attract and retain talent, our turnover rate and the cost of operating our business. We cannot ensure that we will be able to hire or retain the personnel necessary for our operations or that the loss of any personnel will not have a material impact on our financial condition and results of operations.
We may incur unexpected costs from increases in fuel and raw material prices, which could reduce our earnings and cash flows. Our primary commodity exposures are for fuel, petroleum-based resins and steel. The costs for these commodities, as well as the costs of transportation, construction and services necessary for the production and distribution of our products, continue to increase and be volatile. While we may seek to minimize the impact of price increases through higher prices to customers and various cost-saving measures, our earnings and cash flows could be adversely affected in the event these measures are insufficient to cover our costs.
13

THERMO FISHER SCIENTIFIC INC.

Because we rely heavily on third-party package-delivery services, a significant disruption in these services or significant increases in prices may disrupt our ability to ship products, increase our costs and lower our profitability. We ship a significant portion of our products to our customers through independent package delivery companies, such as Federal Express in the U.S. and DHL in Europe. We also maintain a small fleet of vehicles dedicated to the delivery of our products and ship our products through other carriers, including national and regional trucking firms, overnight carrier services and the U.S. Postal Service. If one or more of these third-party package-delivery providers were to experience a major work stoppage, preventing our products from being delivered in a timely fashion or causing us to incur additional shipping costs we could not pass on to our customers, our costs could increase and our relationships with certain of our customers could be adversely affected. In addition, if one or more of these third-party package-delivery providers were to increase prices, and we were not able to find comparable alternatives or make adjustments in our delivery network, our profitability could be adversely affected.
Natural disasters, public health crises, political crises, and other catastrophic events or other events outside of our control may disrupt our facilities or the facilities of third parties on which we depend, and could impact customer spending. We have significant operations in California, near major earthquake faults, which make us susceptible to earthquake risk. An earthquake or other natural disaster (including the effects of climate change such as sea level rise, drought, flooding, wildfires and more intense weather events), could disrupt our operations or impair our critical systems. Any of these disruptions or other events outside of our control, such as strikes or other labor unrest, could have an adverse effect on our results of operations. In addition, if any of our facilities, including our manufacturing or warehouse facilities, or the facilities of our suppliers, third-party service providers, or customers, is affected by natural disasters, such as earthquakes, tsunamis, power shortages or outages, fires, floods or monsoons, public health crises, such as pandemics and epidemics, political crises, such as terrorism, war, political instability or other conflict, or other events outside of our control, such as trade protectionism, strikes or other labor unrest, our results of operations could be adversely affected. Moreover, these types of events could negatively impact customer spending in the impacted regions or depending upon the severity, globally, which could also adversely impact our operating results.
Increasing attention to environmental, social and governance matters may impact our business, financial results, stock price or reputation. We face increasing scrutiny from stakeholders related to our environmental, social and governance (ESG) practices and disclosures, including practices and disclosures related to climate change, diversity and inclusion and governance standards. Investor advocacy groups, certain institutional investors, lenders, investment funds and other influential investors are also increasingly focused on ESG practices and disclosures and in recent years have placed increasing importance on the implications and social cost of their investments. In addition, government organizations are enhancing or advancing legal and regulatory requirements specific to ESG matters. The heightened stakeholder focus on ESG issues related to our business requires the continuous monitoring of various and evolving laws, regulations, standards and expectations and the associated reporting requirements. A failure to adequately meet evolving stakeholder expectations may result in noncompliance, the loss of business, reputational impacts, diluted market valuation, an inability to attract customers and an inability to attract and retain top talent. In addition, if legislation or regulations are enacted or promulgated in the U.S. or in any other jurisdiction in which we do business that impose more stringent restrictions and requirements than our current legal or regulatory obligations, we and companies in our supply chain may experience increased compliance burdens and costs to meet the regulatory obligations, which could cause disruption in the sourcing, manufacturing and distribution of our products and adversely affect our business, financial condition or results of operations. In addition, our adoption of certain standards or mandated compliance to certain requirements could necessitate additional investments that could impact our profitability.
Legal, Quality and Regulatory Risks
Changes in governmental regulations may reduce demand for our products or increase our expenses. We compete in many markets in which we and our customers must comply with federal, state, local and international regulations, such as environmental, health and safety and food and drug regulations. We develop, configure and market our products to meet customer needs created by those regulations. Any significant change in regulations could reduce demand for our products or increase our expenses. For example, we manufacture pharmaceuticals and many of our instruments are marketed to the pharmaceutical industry for use in discovering and developing drugs. Changes in the U.S. Food and Drug Administration’s (the FDA) regulation of the drug discovery and development process could have an adverse effect on the demand for these products.
We are subject to laws and regulations governing government contracts, and failure to address these laws and regulations or comply with government contracts could harm our business by leading to a reduction in revenues associated with these customers. We have agreements relating to the sale of our products to government entities and, as a result, we are subject to various statutes and regulations that apply to companies doing business with the government. The laws governing government contracts differ from the laws governing private contracts and government contracts may contain pricing terms and conditions that are not applicable to private contracts. We are also subject to investigation for compliance with the
14

THERMO FISHER SCIENTIFIC INC.

regulations governing government contracts. A failure to comply with these regulations could result in suspension of these contracts, criminal, civil and administrative penalties or debarment.
Our pharma services offerings are highly complex, and if we are unable to provide quality and timely offerings to our customers, our business could suffer. Our pharma services offerings are highly exacting and complex, due in part to strict quality and regulatory requirements. Our operating results in this business depend on our ability to execute and, when necessary, improve our quality management strategy and systems, and our ability to effectively train and maintain our employee base with respect to quality management. A failure of our quality control systems could result in problems with facility operations or preparation or provision of products. In each case, such problems could arise for a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures, problems with raw materials or environmental factors and damage to, or loss of, manufacturing operations. Such problems could affect production of a particular batch or series of batches of products, requiring the destruction of such products or a halt of facility production altogether.
In addition, our failure to meet required quality standards may result in our failure to timely deliver products to our customers, which in turn could damage our reputation for quality and service. Any such failure could, among other things, lead to increased costs, lost revenues, reimbursement to customers for lost drug product, registered intermediates, registered starting materials, and active pharmaceutical ingredients, other customer claims, damage to and possibly termination of existing customer relationships, time and expense spent investigating the cause and, depending on the cause, similar losses with respect to other batches or products. Production problems in our drug and biologic manufacturing operations could be particularly significant because the cost of raw materials for such manufacturing is often high. If problems in preparation or manufacture of a product or failures to meet required quality standards for that product are not discovered before such product is released to the market, we may be subject to adverse regulatory actions, including product recalls, product seizures, injunctions to halt manufacture and distribution, restrictions on our operations, civil sanctions, including monetary sanctions, and criminal actions. In addition, such problems or failures could subject us to litigation claims, including claims from our customers for reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of which could be significant.
We are subject to product and other liability risks for which we may not have adequate insurance coverage. We may be named as a defendant in product liability or errors and omissions lawsuits, which may allege that products or services we have provided have resulted or could result in an unsafe condition, property damage or injury to end users or financial loss for consumers. Additionally, products currently or previously sold by our environmental and process instruments and radiation measurement and security instruments businesses include fixed and portable instruments used for chemical, radiation and trace explosives detection. These products are used in airports, embassies, cargo facilities, border crossings and other high-threat facilities for the detection and prevention of terrorist acts. If any of these products were to malfunction, it is possible that explosive or radioactive material could fail to be detected by our product, which could lead to product liability claims. In addition, patients involved in our clinical services trials conducted by our clinical development services business or taking drugs approved on the basis of those trials may also bring personal injury claims against us. There are also many other factors beyond our control that could lead to liability claims, such as the reliability and competence of the customers’ operators and the training of such operators.
Any such product liability claims brought against us could be significant and any adverse determination may result in liabilities subject to insurance policy exclusions where insurance would not respond or in excess of our insurance coverage. Although we carry product liability and errors and omissions insurance, we cannot be certain that our current insurance will be sufficient to cover these claims or that it can be maintained on acceptable terms, if at all.
We are required to comply with a wide variety of laws and regulations, and are subject to regulation by various federal, state and foreign agencies. We are subject to various local, state, federal, foreign and transnational laws and regulations, which include the operating and security standards of the FDA, the U.S. Drug Enforcement Agency (the DEA), various state boards of pharmacy, state health departments, the U.S. Department of Health and Human Services (the DHHS), the European Medicines Agency (the EMA), the EU member states and other comparable agencies and, in the future, any changes to such laws and regulations could adversely affect us. In particular, we are subject to laws and regulations concerning current good manufacturing practices and drug safety. Our subsidiaries may be required to register for permits and/or licenses with, and may be required to comply with the laws and regulations of, the DEA, the FDA, the DHHS, foreign agencies including the EMA, and other various state boards of pharmacy, state health departments and/or comparable state agencies as well as certain accrediting bodies depending upon the type of operations and location of product distribution, manufacturing and sale.
The manufacture, distribution and marketing of many of our products and services, including medical devices, and our pharma and clinical development services, are subject to extensive ongoing regulation by the FDA, the DEA, the EMA, and other equivalent local, state, federal and non-U.S. regulatory authorities. In addition, we are subject to inspections by these regulatory authorities. Failure by us or by our customers to comply with the requirements of these regulatory authorities,
15

THERMO FISHER SCIENTIFIC INC.

including without limitation, remediating any inspectional observations to the satisfaction of these regulatory authorities, could result in warning letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution, restrictions on our operations, civil or criminal sanctions, or withdrawal of existing or denial of pending approvals, including those relating to products or facilities. In addition, such a failure could expose us to contractual or product liability claims, contractual claims from our customers, including claims for reimbursement for lost or damaged active pharmaceutical ingredients or personal injury, as well as ongoing remediation and increased compliance costs, any or all of which could be significant. We are the sole manufacturer of a number of pharmaceuticals for many of our customers and a negative regulatory event could impact our customers’ ability to provide products to their customers.
We are also subject to a variety of federal, state, local and international laws and regulations that govern, among other things, the handling, transportation and manufacture of substances that could be classified as hazardous, and we are required to comply with various import laws and export control and economic sanctions laws, which may affect our transactions with certain customers. In certain circumstances, export control and economic sanctions regulations may prohibit the export of certain products, services and technologies. In other circumstances, we may be required to obtain an export license before exporting the controlled item. Compliance with the various import laws that apply to our businesses can restrict our access to, and increase the cost of obtaining, certain products and at times can interrupt our supply of imported inventory. Any noncompliance by us with applicable laws and regulations or the failure to maintain, renew or obtain necessary permits and licenses could result in criminal, civil and administrative penalties and could have an adverse effect on our results of operations.
Our reputation, ability to do business and financial statements may be impaired by improper conduct by any of our employees, agents, business partners or other third parties. We have internal controls and compliance systems to protect the company against acts committed by employees, agents or businesses that we acquire that would violate U.S. and/or non-U.S. laws, including the laws governing payments to government officials, bribery, fraud, kickbacks and false claims, pricing, sales and marketing practices, conflicts of interest, competition, employment practices and workplace behavior, export and import compliance, money laundering and data privacy, but these controls and systems may not be sufficient to prevent every such wrongful act. In particular, the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010 and similar anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from making improper payments to government officials for the purpose of obtaining or retaining business, and we operate in many parts of the world that have experienced governmental corruption to some degree. Any such improper actions or allegations of such acts could damage our reputation and subject us to civil or criminal investigations in the U.S. and in other jurisdictions and related shareholder lawsuits, could lead to substantial civil and criminal, monetary and nonmonetary penalties and could cause us to incur significant legal and investigatory fees. In addition, the government may seek to hold us liable for violations committed by companies which we acquire. We also rely on our suppliers to adhere to our supplier standards of conduct, and material violations of such standards of conduct could occur that could have a material effect on our business, reputation and financial statements. In addition, any allegations of issues resulting from the misuse of our products could, even if untrue, adversely affect our reputation and our customers’ willingness to purchase products from us. Any such allegations could cause us to lose customers and divert our resources from other tasks, which could materially and adversely affect our business and operating results.
Our inability to protect our intellectual property could have a material adverse effect on our business. In addition, third parties may claim that we infringe their intellectual property, and we could suffer significant litigation or licensing expense as a result. We place considerable emphasis on obtaining patent and trade secret protection for significant new technologies, products and processes because of the length of time and expense associated with bringing new products through the development process and into the marketplace. Our success depends in part on our ability to develop patentable products and obtain and enforce patent protection for our products both in the U.S. and in other countries. We own numerous U.S. and foreign patents, and we intend to file additional applications, as appropriate, for patents covering our products. Patents may not be issued for any pending or future patent applications owned by or licensed to us, and the claims allowed under any issued patents may not be sufficiently broad to protect our technology. Any issued patents owned by or licensed to us may be challenged, invalidated or circumvented, and the rights under these patents may not provide us with competitive advantages. In addition, competitors may design around our technology or develop competing technologies. Intellectual property rights may also be unavailable or limited in some foreign countries, which could make it easier for competitors to capture increased market position. We could incur substantial costs to defend ourselves in suits brought against us or in suits in which we may assert our patent rights against others. An unfavorable outcome of any such litigation could materially adversely affect our business and results of operations.
We also rely on trade secrets and proprietary know-how with which we seek to protect our products, in part, by confidentiality agreements with our collaborators, employees and consultants. These agreements may not adequately protect our trade secrets and other proprietary rights. These agreements may be breached and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently developed by our competitors.
16

THERMO FISHER SCIENTIFIC INC.

We also depend in part on our trademarks and the strength of our proprietary brands, which we consider important to our business. If we are unable to protect or preserve the value of our intellectual property rights for any reason, including our inability to successfully defend against counterfeit, knock offs, grey-market, infringing or otherwise unauthorized products, our brand and reputation could be damaged, and our business may be harmed.
Third parties may assert claims against us to the effect that we are infringing on their intellectual property rights. In the event that a claim relating to intellectual property is asserted against us, or third parties not affiliated with us hold pending or issued patents that relate to our products or technology, we may seek licenses to such intellectual property or challenge those patents. However, we may be unable to obtain these licenses on commercially reasonable terms, if at all, and our challenge of the patents may be unsuccessful. Our failure to obtain the necessary licenses or other rights could prevent the sale, manufacture, or distribution of our products and, therefore, could have a material adverse effect on our business, financial condition and results of operations.
Risks Relating to Financial Profile
Fluctuations in our effective tax rate may adversely affect our results of operations and cash flows. As a global company, we are subject to taxation in numerous countries, states and other jurisdictions. In preparing our financial statements, we record the amount of tax that is payable in each of the countries, states and other jurisdictions in which we operate. Our future effective tax rate, however, may be lower or higher than experienced in the past due to numerous factors, including a change in the mix of our profitability from country to country, changes in accounting for income taxes, the results of examinations and audits of our tax filings and recently enacted and future changes in tax laws in jurisdictions in which we operate. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations, which could have an adverse effect on our business, results of operations and cash flows.
Our existing and future indebtedness may restrict our investment opportunities or limit our activities and negatively impact our credit ratings. As of December 31, 2022, we had approximately $34.49 billion in outstanding indebtedness. In addition, we have availability to borrow under a revolving credit facility that provides for up to $5.00 billion of unsecured multi-currency revolving credit (the Facility). We may also obtain additional long-term debt and lines of credit to meet future financing needs, which would have the effect of increasing our total leverage.
Our leverage could have negative consequences, including increasing our vulnerability to adverse economic and industry conditions, limiting our ability to obtain additional financing and limiting our ability to acquire new products and technologies through strategic acquisitions.
Our ability to make scheduled payments, refinance our obligations or obtain additional financing will depend on our future operating performance and on economic, financial, competitive and other factors beyond our control. Our business may not generate sufficient cash flow to meet our obligations. If we are unable to service our debt, refinance our existing debt or obtain additional financing, we may be forced to delay strategic acquisitions, capital expenditures or research and development expenditures.
Additionally, the agreements governing our debt require that we maintain a financial ratio, and contain affirmative and negative covenants that restrict our activities by, among other limitations, limiting our ability to incur additional indebtedness, merge or consolidate with other entities and create liens. The covenants in the Facility include a Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Net Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter.
Our ability to comply with these financial restrictions and covenants is dependent on our future performance, which is subject to prevailing economic conditions and other factors, including factors that are beyond our control such as the impact of foreign exchange rates and interest rates. Our failure to comply with any of these restrictions or covenants may result in an event of default under the applicable debt instrument, which could permit acceleration of the debt under that instrument and require us to prepay that debt before its scheduled due date. Also, an acceleration of the debt under certain of our debt instruments would trigger an event of default under other of our debt instruments.
Item 1B.    Unresolved Staff Comments
None.
Item 2.    Properties
The company owns and leases office, engineering, laboratory, production and warehouse space throughout the world.
17

THERMO FISHER SCIENTIFIC INC.
Item 3.    Legal Proceedings
There are various lawsuits and claims against the company involving product liability, intellectual property, employment and commercial issues. See Note 12 to our Consolidated Financial Statements – Commitments and Contingencies.
Item 4.    Mine Safety Disclosures
Not applicable.
PART II
Item 5.    Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market Price of Common Stock
Our common stock is traded on the New York Stock Exchange under the symbol TMO.
Holders of Common Stock
As of February 4, 2023, the company had 2,460 holders of record of its common stock. This does not include holdings in street or nominee names.
Issuer Purchases of Equity Securities
A summary of the share repurchase activity for the company's fourth quarter of 2022 follows:
Period Total number of shares purchased Average price paid per share Total number of shares purchased as part of publicly announced plans or programs (1) Maximum dollar amount of shares that may yet be purchased under the plans or programs (1)
(in millions)
Fiscal October (Oct. 2 - Nov. 5) 1,989,832  $ 502.55  1,989,832  $ — 
Fiscal November (Nov. 6 - Dec. 3) —  —  —  4,000 
Fiscal December (Dec. 4 - Dec. 31) —  —  —  4,000 
Total fourth quarter 1,989,832  $ 502.55  1,989,832  $ 4,000 
(1) On September 23, 2021, the Board of Directors authorized the repurchase of up to $3.00 billion of the company’s common stock. All of the shares of common stock repurchased by the company during the fourth quarter were purchased under this program, depleting the 2021 authorization. On November 10, 2022, the Board of Directors authorized the repurchase of up to $4.00 billion of the company’s common stock. Early in the first quarter of 2023, the company repurchased $3.00 billion of the company’s common stock (5.2 million shares). At February 23, 2023, $1.00 billion was available for future repurchases of the company’s common stock under this authorization.
Item 6.    Reserved
Not applicable.
Item 7.    Management’s Discussion and Analysis of Financial Condition and Results of Operations
Reference is made throughout this Management’s Discussion and Analysis of Financial Condition and Results of Operations to Notes to the Consolidated Financial Statements, which begin on page F-1 of this report. Management’s Discussion and Analysis of Financial Condition and Results of Operations for 2020 is included in Item 7 of the company’s 2021 Annual Report on Form 10-K filed with the Securities and Exchange Commission.
The company refers to various amounts or measures not prepared in accordance with generally accepted accounting principles (non-GAAP measures). These non-GAAP measures are further described and reconciled to their most directly comparable amount or measure under the section “Non-GAAP Measures” later in this Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Overview
Thermo Fisher Scientific Inc. enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through
18

THERMO FISHER SCIENTIFIC INC.
diagnostics and the development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. The company’s operations fall into four segments (Note 4): Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and Biopharma Services.
Consolidated Results
(Dollars in millions except per share amounts) 2022 2021 Change
Revenues
 $ 44,915  $ 39,211  15  %
GAAP operating income $ 8,393  $ 10,028  (16) %
GAAP operating income margin 18.7  % 25.6  % (6.9)  pt
Adjusted operating income (non-GAAP measure)
 $ 10,985  $ 12,138  (9) %
Adjusted operating income margin (non-GAAP measure)
 24.5  % 31.0  % (6.5)  pt
GAAP diluted earnings per share attributable to Thermo Fisher Scientific Inc. $ 17.63  $ 19.46  (9) %
Adjusted earnings per share (non-GAAP measure)
 $ 23.24  $ 25.13  (8) %
Organic Revenue Growth
Revenue growth 15  %
Impact of acquisitions 18  %
Impact of currency translation (3) %
Organic revenue growth* (non-GAAP measure)
 0  %
*    Results may not sum due to rounding.
Since 2020, the Life Sciences Solutions and Specialty Diagnostics segments as well as the laboratory products business have supported COVID-19 diagnostic testing, scaling and evolving their molecular diagnostics solutions and plastic consumables businesses to respond to the ongoing COVID-19 pandemic. The biosciences and bioproduction businesses have expanded their capacity to meet the needs of pharma and biotech customers as they have expanded their own production volumes to meet global vaccine manufacturing requirements. Additionally, our pharma services business has provided our pharma and biotech customers with the services they needed to develop and produce vaccines and therapies globally. While these positive impacts are expected to continue through 2023, the duration and extent of future revenues from such sales are uncertain and dependent primarily on customer testing as well as therapy and vaccine demand. Sales of products related to COVID-19 testing were $3.11 billion and $7.26 billion in 2022 and 2021, respectively.
During 2022 demand from pharma and biotech customers was very strong, driven by our differentiated customer value proposition and trusted partner status. We saw good growth in the academic and government market as we remain well positioned to meet customer needs. The industrial and applied market was strong, driven by robust demand for our analytical instruments serving our semi-conductor and materials science customers. The diagnostics and healthcare market declined due to decreased demand for COVID-19 testing products. During 2022, robust sales growth in North America and the Asia Pacific region, including China, was partially offset by a decline in COVID-19 testing demand. In Europe, strong sales were more than offset during 2022 due to lower COVID-19 testing demand. Contributions to organic revenue during 2022 were driven by the Laboratory Products and Biopharma Services and Analytical Instruments segments, as offset by the Life Sciences Solutions and Specialty Diagnostics segments.
The company continues to execute its proven growth strategy which consists of three pillars:
•Developing high-impact, innovative new products,
•Leveraging our scale in high-growth and emerging markets, and
•Delivering a unique value proposition to our customers.
GAAP operating income margin and adjusted operating income margin decreased in 2022 due primarily to lower COVID-19 testing volumes, continued strategic growth investments, and the expected impact of incorporating recent acquisitions. This was partially offset by strong pricing realization across all segments to address higher inflation while also driving strong productivity. GAAP operating income margin in 2022 was also impacted by higher amortization expense as a result of 2021 acquisitions.
The company’s references to strategic growth investments generally refer to targeted spending for enhancing commercial capabilities, including expansion of geographic sales reach and e-commerce platforms, marketing initiatives, expanded service and operational infrastructure, research and development projects and other expenditures to enhance the customer experience, as well as incentive compensation and recognition for employees. The company’s references throughout this discussion to
19

THERMO FISHER SCIENTIFIC INC.
productivity improvements generally refer to improved cost efficiencies from its Practical Process Improvement (PPI) business system including reduced costs resulting from implementing continuous improvement methodologies, global sourcing initiatives, a lower cost structure following restructuring actions, including headcount reductions and consolidation of facilities, and low cost region manufacturing.
Notable Recent Acquisitions
On January 15, 2021, the company acquired, within the Laboratory Products and Biopharma Services segment, the Belgium-based European viral vector manufacturing business of Groupe Novasep SAS. The European viral vector manufacturing business provides manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. The acquisition expands the segment’s capabilities for cell and gene vaccines and therapies.
On February 25, 2021, the company acquired, within the Life Sciences Solutions segment, Mesa Biotech, Inc., a U.S.-based molecular diagnostic company. Mesa Biotech has developed and commercialized a PCR based rapid point-of-care testing platform available for detecting infectious diseases including COVID-19. The acquisition enables the company to accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care.
On September 30, 2021, the company assumed operating responsibility, within the Laboratory Products and Biopharma Services segment, of a new state-of-the-art biologics manufacturing facility in Lengnau, Switzerland from CSL Limited to perform pharma services for CSL with capacity to serve other customers as well.
On December 8, 2021, the company acquired, within the Laboratory Products and Biopharma Services segment, PPD, Inc., a U.S.-based global provider of clinical research services to the pharma and biotech industry. The addition of PPD’s clinical research services enhances our offering to biotech and pharma customers by enabling them to accelerate innovation and increase their productivity within the drug development process.
On December 30, 2021, the company acquired, within the Life Sciences Solutions segment, PeproTech, Inc., a U.S.-based developer and manufacturer of recombinant proteins. PeproTech provides bioscience reagents known as recombinant proteins, including cytokines and growth factors. The acquisition expands the segment’s bioscience offerings.
On January 3, 2023, the company acquired, within the Specialty Diagnostics segment, The Binding Site Group, a U.K.-based provider of specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The acquisition expands the segment’s portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma.
Segment Results
The company’s management evaluates segment operating performance using operating income before certain charges/credits as defined in Note 4. Accordingly, the following segment data are reported on this basis.
(Dollars in millions) 2022 2021
Revenues
Life Sciences Solutions
 $ 13,532  $ 15,631 
Analytical Instruments
 6,624  6,069 
Specialty Diagnostics
 4,763  5,659 
Laboratory Products and Biopharma Services
 22,511  14,862 
Eliminations
 (2,515) (3,010)
Consolidated revenues
 $ 44,915  $ 39,211 
Life Sciences Solutions
Organic* (non-GAAP measure)
(Dollars in millions) 2022 2021 Total
Change		 Currency
Translation		 Acquisitions/ Divestitures
Revenues $ 13,532  $ 15,631  (13) % (3) % 1  % (12) %
Segment income $ 5,582  $ 7,817  (29) %
Segment income margin 41.2  % 50.0  % (8.8)  pt
The decrease in organic revenues in 2022 was primarily due to lower revenue in the genetic sciences business, driven by moderation in testing demand to diagnose COVID-19, partially offset by growth in the bioproduction business. The decrease in segment income margin resulted primarily from business mix and strategic growth investments, partially offset by productivity improvements.
20

THERMO FISHER SCIENTIFIC INC.
Analytical Instruments
Organic* (non-GAAP measure)
(Dollars in millions) 2022 2021 Total
Change		 Currency
Translation		 Acquisitions/ Divestitures
Revenues $ 6,624  $ 6,069  9  % (5) % 0  % 14  %
Segment income 1,507  1,197  26  %
Segment income margin 22.8  % 19.7  % 3.1 pt
The increase in organic revenues in 2022 was due to increased demand across all the segment’s businesses, with particular strength in the electron microscopy and chromatography and mass spectrometry businesses. The increase in segment income margin resulted primarily from profit on higher sales, productivity improvements and business mix, offset in part by strategic growth investments.
Specialty Diagnostics
Organic* (non-GAAP measure)
(Dollars in millions) 2022 2021 Total
Change		 Currency
Translation		 Acquisitions/ Divestitures
Revenues $ 4,763  $ 5,659  (16) % (3) % 0  % (13) %
Segment income 1,024  1,280  (20) %
Segment income margin 21.5  % 22.6  % (1.1)  pt
The decrease in organic revenues in 2022 was primarily driven by products addressing diagnosis of COVID-19, partially offset by growth in the immunodiagnostics and transplant diagnostics businesses. The decrease in segment income margin was primarily due to lower COVID-19 testing volume, largely offset by productivity improvements and positive business mix. Segment income margin in 2021 was also impacted by a $13 million credit to cost of product revenue as a result of changing the method of accounting for inventories.
Laboratory Products and Biopharma Services
Organic* (non-GAAP measure)
(Dollars in millions) 2022 2021 Total
Change		 Currency
Translation		 Acquisitions/ Divestitures
Revenues $ 22,511  $ 14,862  51  % (3) % 45  % 10  %
Segment income 2,872  1,844  56  %
Segment income margin 12.8  % 12.4  % 0.4 pt
The increase in organic revenues in 2022 was primarily due to higher sales across each of the segment’s businesses, with particular strength in the pharma services business and research and safety market channel. PPD, the company’s clinical research business, contributed $7.11 billion of revenue during 2022. The increase in segment income margin was primarily due to the benefit of recent acquisitions, profit on higher sales, and productivity improvements, offset in part by strategic growth investments. Segment income margin in 2021 was also impacted by a $20 million credit to cost of product revenue as a result of changing the method of accounting for inventories.
*    Results may not sum due to rounding
Non-operating Items
(Dollars in millions) 2022 2021
Net interest expense
 $ 454  $ 493 
GAAP other income/(expense) (104) (694)
Adjusted other income/(expense) (non-GAAP measure)
 13  38 
GAAP tax rate 9.0  % 12.5  %
Adjusted tax rate (non-GAAP measure)
 13.0  % 14.6  %

Net interest expense (interest expense less interest income) decreased due primarily to lower average interest rates on debt and higher average interest rates on cash balances, partially offset by the increase in debt to finance the acquisition of PPD and for general corporate purposes. See additional discussion under the caption “Liquidity and Capital Resources” below.
GAAP other income/(expense) and adjusted other income/(expense) includes currency transaction gains, losses on non-operating monetary assets and liabilities, and net periodic pension benefit cost/income, excluding the service cost component. GAAP other income/(expense) in 2022 also includes $160 million of net losses on investments, $26 million of losses on the
21

THERMO FISHER SCIENTIFIC INC.
early extinguishment of debt (Note 10), partially offset by $67 million of net gains on derivative instruments to address certain foreign currency risks and $2 million of net settlement gains on pension plans. GAAP other income/(expense) in 2021 also includes $767 million of losses on the early extinguishment of debt and $36 million of financing costs associated with obtaining bridge financing commitments in connection with the agreement to acquire PPD (Note 2), offset in part by $66 million of net gains on investments.
The company’s GAAP and adjusted tax rates decreased in 2022 compared to 2021 primarily due to releases of valuation allowances of $87 million in 2022 in jurisdictions where the deferred tax assets are now expected to be realized. The company’s 2022 GAAP tax rate was also impacted by changes in tax rates and higher amortization expense as a result of 2021 acquisitions, as well as a net benefit of $208 million resulting from tax audit settlements (see Note 8). The company’s 2021 GAAP and adjusted tax rates were also impacted by income tax benefits on intra-entity transactions totaling $284 million.
The effective tax rate in both 2022 and 2021 was also affected by relatively significant earnings in lower tax jurisdictions. Due primarily to the non-deductibility of intangible asset amortization for tax purposes, the company’s cash payments for income taxes were higher than its income tax expense for financial reporting purposes and totaled $1.23 billion and $2.18 billion in 2022 and 2021, respectively.
The company expects its GAAP effective tax rate in 2023 will be between 7% and 9% based on currently forecasted rates of profitability in the countries in which the company conducts business and expected generation of foreign tax credits. The effective tax rate can vary significantly from period to period as a result of discrete income tax factors and events. The company expects its adjusted tax rate will be approximately 11% in 2023.
The company has operations and a taxable presence in approximately 70 countries outside the U.S. Some of these countries have lower tax rates than the U.S. The company’s ability to obtain a benefit from lower tax rates outside the U.S. is dependent on its relative levels of income in countries outside the U.S. and on the statutory tax rates in those countries. Based on the dispersion of the company’s non-U.S. income tax provision among many countries, the company believes that a change in the statutory tax rate in any individual country is not likely to materially affect the company’s income tax provision or net income, aside from any resulting one-time adjustment to the company’s deferred tax balances to reflect a new rate.
Liquidity and Capital Resources
The company’s proven growth strategy has enabled it to generate free cash flow as well as access the capital markets. The company deploys its capital primarily via mergers and acquisitions and secondarily via share buybacks and dividends.
December 31, December 31,
(In millions) 2022 2021
Cash and cash equivalents $ 8,524  $ 4,477 
Total debt 34,488  34,870 
Approximately half of the company’s cash balances and cash flows from operations are from outside the U.S. The company uses its non-U.S. cash for needs outside of the U.S. including acquisitions, capacity expansion, and repayment of third-party foreign debt by foreign subsidiaries. In addition, the company also transfers cash to the U.S. using non-taxable returns of capital as well as dividends where the related U.S. dividend received deduction or foreign tax credit equals any tax cost arising from the dividends. As a result of using such means of transferring cash to the U.S., the company does not expect any material adverse liquidity effects from its significant non-U.S. cash balances for the foreseeable future.
The company believes that its existing cash and cash equivalents and its future cash flow from operations together with available borrowing capacity under its revolving credit agreement will be sufficient to meet the cash requirements of its existing businesses for the foreseeable future, including at least the next 24 months.
As of December 31, 2022, the company’s short-term debt totaled $5.58 billion. The company has a revolving credit facility with a bank group that provides up to $5.00 billion of unsecured multi-currency revolving credit (Note 10). If the company borrows under this facility, it intends to leave undrawn an amount equivalent to outstanding commercial paper to provide a source of funds in the event that commercial paper markets are not available. As of December 31, 2022, no borrowings were outstanding under the company’s revolving credit facility, although available capacity was reduced by immaterial outstanding letters of credit.
22

THERMO FISHER SCIENTIFIC INC.
(In millions) 2022 2021
Net cash provided by operating activities
 $ 9,154  $ 9,312 
Net cash used in investing activities
 (2,159) (21,932)
Net cash (used in) provided by financing activities
 (2,810) 6,581 
Free cash flow (non-GAAP measure)
 6,935  6,809 
Operating Activities
During 2022, cash provided by income was offset in part by investments in working capital. Increases in accounts receivable and inventories used cash of $0.43 billion and $0.83 billion, respectively, primarily to support growth in sales. An increase in accounts payable provided cash of $0.65 billion. Cash payments for income taxes were $1.23 billion during 2022.
During 2021, cash provided by income was offset in part by investments in working capital. Increases in accounts receivable and inventories used cash of $0.20 billion and $1.07 billion, respectively, primarily to support growth in sales. An increase in accounts payable provided cash of $0.48 billion. Changes in other assets and other liabilities used cash of $0.72 billion primarily due to the timing of tax and incentive compensation payments. Cash payments for income taxes were $2.18 billion during 2021.
The company is contingently liable with respect to certain legal proceedings and related matters. An unfavorable outcome that differs materially from current accrual estimates, if any, for one or more of the matters described under the heading “Product Liability, Workers Compensation and Other Personal Injury Matters,” in Note 12 could have a material adverse effect on the company’s financial position as well as its results of operations and cash flows.
Investing Activities
During 2022, acquisitions used cash of $0.04 billion. The company’s investing activities were principally for the purchase of property, plant and equipment for capacity and capability investments.
During 2021, acquisitions used cash of $19.40 billion. The company’s investing activities also included the purchase of $2.52 billion of property, plant and equipment.
The company expects that for all of 2023, expenditures for property, plant and equipment, net of disposals, will be approximately $2.0 billion.
Financing Activities
During 2022, issuance of senior notes provided $3.19 billion in cash. Repayment of senior notes and net commercial paper activity used cash of $0.38 billion and $2.16 billion, respectively. The company’s financing activities also included the repurchase of $3.00 billion of the company’s common stock (5.3 million shares) and the payment of $0.46 billion in cash dividends. On September 23, 2021, the Board of Directors authorized the repurchase of up to $3.00 billion of the company’s common stock. All of the shares of common stock repurchased by the company during the fourth quarter of 2022 were purchased under this program, depleting the 2021 authorization. On November 10, 2022, the Board of Directors authorized the repurchase of up to $4.00 billion of the company’s common stock. Early in the first quarter of 2023, the company repurchased $3.00 billion of the company's common stock (5.2 million shares). At February 23, 2023, authorization remained for $1.00 billion of future repurchases of the company’s common stock.
During 2021, issuance of senior notes provided $18.14 billion of cash. A net increase in commercial paper obligations provided cash of $2.51 billion. Repayment of debt used cash of $11.74 billion, including $4.30 billion to repay the debt assumed in the acquisition of PPD. The company’s financing activities also included the repurchase of $2.00 billion of the company's common stock (4.1 million shares) and the payment of $0.40 billion in cash dividends.
In addition to the obligations on the balance sheet at December 31, 2022, which include, but are not limited to, debt (Note 10), unrecognized tax benefits (Note 8), operating leases (Note 11), pension obligations (Note 7) and contingent consideration (Note 14), the company has entered into unconditional purchase obligations, in the ordinary course of business, that include agreements to purchase goods, services or fixed assets and to pay royalties (Note 12).
Non-GAAP Measures
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures such as organic revenue growth, which is reported revenue growth, excluding the impacts of revenues from acquired/divested businesses and the effects of currency translation. We report organic revenue growth because Thermo Fisher management believes that in order to understand the company’s short-term and long-term financial trends, investors may wish to consider the impact of acquisitions/divestitures and foreign currency translation on
23

THERMO FISHER SCIENTIFIC INC.
revenues. Thermo Fisher management uses organic revenue growth to forecast and evaluate the operational performance of the company as well as to compare revenues of current periods to prior periods.
We report adjusted operating income, adjusted operating income margin, adjusted other income/(expense), adjusted tax rate, and adjusted EPS. We believe that the use of these non-GAAP financial measures, in addition to GAAP financial measures, helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company’s core operating performance, especially when comparing such results to previous periods, forecasts, and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-making and for compensation purposes. To calculate these measures we exclude, as applicable:
•Certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition, significant transaction/acquisition-related costs, including changes in estimates of contingent acquisition-related consideration, and other costs associated with obtaining short-term financing commitments for pending/recent acquisitions. We exclude these costs because we do not believe they are indicative of our normal operating costs.
•Costs/income associated with restructuring activities and large-scale abandonments of product lines, such as reducing overhead and consolidating facilities. We exclude these costs because we believe that the costs related to restructuring activities and large-scale abandonment of product lines are not indicative of our normal operating costs.
•Equity in earnings/losses of unconsolidated entities; impairments of long-lived assets; and certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, including gains/losses on investments, the sale of businesses, product lines, and real estate, significant litigation-related matters, curtailments/settlements of pension plans, and the early retirement of debt. We exclude these items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.
•The expense associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions may be allocated to intangible assets that have lives of up to 20 years. Exclusion of the amortization expense allows comparisons of operating results that are consistent over time for both our newly acquired and long-held businesses and with both acquisitive and non-acquisitive peer companies.
•The tax impacts of the above items and the impact of significant tax audits or events (such as changes in deferred taxes from enacted tax rate/law changes), the latter of which we exclude because they are outside of our normal operations and difficult to forecast accurately for future periods.
We report free cash flow, which is operating cash flow excluding net capital expenditures, to provide a view of the continuing operations’ ability to generate cash for use in acquisitions and other investing and financing activities. The company also uses this measure as an indication of the strength of the company. Free cash flow is not a measure of cash available for discretionary expenditures since we have certain non-discretionary obligations such as debt service that are not deducted from the measure.
The non-GAAP financial measures of the company’s results of operations and cash flows included in this Form 10-K are not meant to be considered superior to or a substitute for the company’s results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth within the “Overview” and “Results of Operations” sections and below.
(Dollars in millions except per share amounts) 2022 2021
Reconciliation of adjusted operating income and adjusted operating income margin
GAAP operating income $ 8,393  18.7  % $ 10,028  25.6  %
Cost of revenues adjustments (a)
 46  0.1  % 8  0.0  %
Selling, general and administrative expenses adjustments (b)
 37  0.1  % 144  0.4  %
Restructuring and other costs (c)
 114  0.3  % 197  0.5  %
Amortization of acquisition-related intangible assets 2,395  5.3  % 1,761  4.5  %
Adjusted operating income (non-GAAP measure)
 $ 10,985  24.5  % $ 12,138  31.0  %
Reconciliation of adjusted other income/(expense)
GAAP other income/(expense) $ (104) $ (694)
Adjustments (d) 117  732 
Adjusted other income/(expense) (non-GAAP measure)
 $ 13  $ 38 
24

THERMO FISHER SCIENTIFIC INC.
(Dollars in millions except per share amounts) 2022 2021
Reconciliation of adjusted tax rate
GAAP tax rate 9.0  % 12.5  %
Adjustments (e) 4.0  % 2.1  %
Adjusted tax rate (non-GAAP measure)
 13.0  % 14.6  %
Reconciliation of adjusted earnings per share
GAAP diluted earnings per share (EPS) attributable to Thermo Fisher Scientific Inc. $ 17.63  $ 19.46 
Cost of revenues adjustments (a) 0.12  0.02 
Selling, general and administrative expenses adjustments (b) 0.09  0.36 
Restructuring and other costs (c) 0.29  0.50 
Amortization of acquisition-related intangible assets 6.07  4.43 
Other income/expense adjustments (d) 0.30  1.84 
Provision for income taxes adjustments (e) (1.70) (1.49)
Equity in earnings/losses of unconsolidated entities 0.44  0.01 
Adjusted EPS (non-GAAP measure)
 $ 23.24  $ 25.13 
Reconciliation of free cash flow
GAAP net cash provided by operating activities $ 9,154  $ 9,312 
Purchases of property, plant and equipment (2,243) (2,523)
Proceeds from sale of property, plant and equipment 24  20 
Free cash flow (non-GAAP measure)
 $ 6,935  $ 6,809 
(a) Adjusted results exclude charges for the sale of inventories revalued at the date of acquisition. Adjusted results in 2022 also exclude $27 million of inventory write-downs associated with large-scale abandonment of product lines.
(b) Adjusted results exclude certain third-party expenses, principally transaction/integration costs related to recent acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, and charges associated with product liability litigation.
(c) Adjusted results exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, charges/credits for environmental-related matters, abandoned facility and other expenses of headcount reductions within several businesses and real estate consolidations. Adjusted results in 2022 also exclude $14 million of gain on the sale of intellectual property. Adjusted results in 2021 also exclude $122 million of charges for impairments of acquired intangible assets and $35 million of charges for compensation due to employees at recently acquired businesses at the date of acquisition.
(d) Adjusted results exclude net gains/losses on investments and losses on the early extinguishment of debt. Adjusted results in 2022 also exclude $67 million of net gains on derivative instruments to address certain foreign currency risks and $2 million of net settlement gains for pension plans. Adjusted results in 2021 also exclude $36 million of charges for amortization of bridge loan commitment fees related to a pending acquisition.
(e) Adjusted provision for income taxes excludes incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes and the tax impacts from audit settlements (including a $658 million benefit from an audit settlement in 2022). Adjusted results in 2022 also exclude a $423 million charge for the impact of deferred tax realizability assessments as a result of audit settlements.
Critical Accounting Policies and Estimates
The company’s discussion and analysis of its financial condition and results of operations is based upon its financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent liabilities. On an on-going basis, management evaluates its estimates, including those related to acquisition-related measurements and income taxes. Management believes the most complex and sensitive judgments, because of their significance to the consolidated financial statements, result primarily from the need to make estimates about the effects of matters that are inherently uncertain. Management bases its estimates on historical experience, current market and economic conditions and other assumptions that management believes are reasonable. The results of these estimates form the basis for judgments about the carrying value of assets and liabilities where the values are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
25

THERMO FISHER SCIENTIFIC INC.
The company believes the following represent its critical accounting policies and estimates used in the preparation of its financial statements:
Acquisition-related Measurements
Business Combinations
The company uses assumptions and estimates in determining the fair value of assets acquired and liabilities assumed in a business combination. The determination of the fair value of intangible assets, which represent a significant portion of the purchase price in many of the company’s acquisitions, requires the use of significant judgment with regard to (i) the fair value and (ii) whether such intangibles are amortizable or non-amortizable and, if the former, the period and the method by which the intangible asset will be amortized. The company estimates the fair value of acquisition-related intangible assets principally based on projections of cash flows that will arise from identifiable intangible assets of acquired businesses, which include estimates of customer attrition and technology obsolescence rates. The projected cash flows are discounted to determine the present value of the assets at the dates of acquisition. See Note 2 for additional information about our recent business combinations.
Goodwill and Indefinite-lived Intangible Assets
The company evaluates goodwill and indefinite-lived intangible assets for impairment annually and when events occur or circumstances change that would more likely than not reduce the fair value of an asset below its carrying amount. Events or circumstances that might require an interim evaluation include unexpected adverse business conditions, economic factors, unanticipated technological changes or competitive activities, loss of key personnel and acts by governments and courts, among others. Goodwill and indefinite-lived intangible assets totaled $41.20 billion and $1.24 billion, respectively, at December 31, 2022 (see Note 1 for additional information). Estimates of discounted future cash flows require assumptions related to revenue and operating income growth rates, discount rates and other factors. For the goodwill impairment tests, the company also considers (i) peer revenues and earnings trading multiples from companies that have operational and financial characteristics that are similar to the respective reporting units and (ii) estimated weighted average costs of capital. Different assumptions from those made in the company’s analysis could materially affect projected cash flows and the company’s evaluation of goodwill and indefinite-lived intangible assets for impairment.
Except as described below, the company performed the quantitative goodwill impairment test for all of its reporting units and indefinite-lived intangible assets. Determinations of fair value based on projections of discounted cash flows, which decreased from the prior year projections primarily due to higher discount rates, and based on peer revenues and earnings trading multiples, which also decreased from the prior year, were sufficient to conclude that no impairments of goodwill or indefinite-lived intangible assets existed at the end of the tenth fiscal month of 2022, the date of the company’s annual impairment testing. There were no interim impairments of goodwill or indefinite-lived intangible assets in 2022. There can be no assurance, however, that adverse events or conditions will not cause the fair values of these assets to decline. Should the fair values of the company’s reporting units or indefinite-lived intangible assets decline because of reduced operating performance, market declines, or other indicators of impairment, or as a result of changes in the discount rates, charges for impairment may be necessary.
With the completion of the PPD acquisition in December 2021, the company established two new reporting units that solely consist of the legacy PPD businesses, the book carrying values of which equaled their fair values as of the acquisition date. During its annual 2022 goodwill impairment assessments, the company performed qualitative assessments of these reporting units and determined that no events had occurred and no circumstances had changed that would more-likely-than-not reduce the fair values of the reporting units below their carrying amounts. As a result, the company did not perform the quantitative goodwill impairment tests for these reporting units. Given that the fair values of the reporting units were unlikely to be substantially in excess of their carrying values as of the annual 2022 assessment date, relatively small decreases in future cash flows versus anticipated results, decreases in peer trading multiples and/or increases in weighted average costs of capital could result in impairment of goodwill. The reporting units consisting of the legacy PPD businesses had $13.41 billion of goodwill, and an overall carrying value of $19.30 billion as of December 31, 2022.
Definite-lived Intangible Assets
Definite-lived intangible assets totaled $16.21 billion at December 31, 2022 (see Note 1 for additional information). Certain definite-lived intangible assets have largely independent cash flows. The company reviews these definite-lived intangible assets for impairment individually when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. Actual cash flows arising from a particular intangible asset could vary from projected cash flows, which could imply different carrying values from those established at the dates of acquisition and which could result in impairment of such asset. Most of the company’s definite-lived intangible assets are used in conjunction with other assets, such as property, plant and equipment and operating lease right-of-use assets. In these situations, the company considers
26

THERMO FISHER SCIENTIFIC INC.
the asset groups to be the units of account for impairment testing. The company recorded impairments of $0.12 billion in 2021 (see Note 16).
Income Taxes
Unrecognized Tax Benefits
In the ordinary course of business there is inherent uncertainty in quantifying the company’s income tax positions. The company assesses income tax positions and records tax benefits for all years subject to examination based upon management’s evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the company has recorded the largest amount of tax benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements. Should tax return positions that the company expects are sustainable not be sustained upon audit, the company could be required to record an incremental tax provision for such taxes. The company’s liability for these unrecognized tax benefits totaled $0.57 billion at December 31, 2022, compared to $1.12 billion at December 31, 2021, primarily as a result of an audit settlement (see Note 8).
The company operates in numerous countries under many legal forms and, as a result, is subject to the jurisdiction of numerous domestic and non-U.S. tax authorities, as well as to tax agreements and treaties among these governments. Determination of taxable income in any jurisdiction requires the company to interpret the related tax laws and regulations and the use of estimates and assumptions regarding significant future events, such as the amount, timing and character of deductions, permissible revenue recognition methods under the tax law and the sources and character of income and tax credits. Changes in tax laws, regulations, agreements and treaties, currency exchange restrictions or the company’s level of operations or profitability in each taxing jurisdiction could have an impact upon the amount of current and deferred tax balances and hence the company’s net income.
Valuation Allowances
The company estimates the degree to which tax assets will result in a benefit, after consideration of all positive and negative evidence, and provides a valuation allowance for tax assets that it believes will more likely than not go unused. In situations in which the company has been able to determine that its deferred tax assets will be realized, that determination generally relies on future reversals of taxable temporary differences and expected future taxable income. If it becomes more likely than not that a tax asset will be used, the company reverses the related valuation allowance. Any such reversals are recorded as a reduction of the company’s tax provision. The company’s tax valuation allowance totaled $1.32 billion at December 31, 2022, compared to $0.97 billion at December 31, 2021, primarily driven by the assessment of additional tax assets resulting from an audit settlement during the year (see Note 8). Should the company’s actual future taxable income by tax jurisdiction vary from estimates, additional allowances or reversals thereof may be necessary.
Recent Accounting Pronouncements
A description of recently issued accounting standards is included under the heading “Recent Accounting Pronouncements” in Note 1.
Item 7A.    Quantitative and Qualitative Disclosures About Market Risk
The company is exposed to market risk from changes in interest rates and currency exchange rates, which could affect its future results of operations and financial condition. The company manages its exposure to these risks through its regular operating and financing activities. The company has periodically hedged interest rate risks of fixed-rate instruments with offsetting interest rate swaps. Additionally, the company uses short-term forward and option contracts primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates. Such exposures result from purchases, sales, cash and intercompany loans that are denominated in currencies other than the functional currencies of the respective operations. The currency-exchange contracts principally hedge transactions denominated in euro, British pounds sterling, Singapore dollars, Japanese yen, Hong Kong dollars, Czech koruna and Swedish krona. Income and losses arising from these derivative contracts are recognized as offsets to losses and income resulting from the underlying exposure being hedged. The company does not enter into speculative derivative agreements.
Interest Rates
The company is exposed to changes in interest rates while conducting normal business operations as a result of ongoing investing and financing activities, which affect the company’s debt as well as cash and cash equivalents. As of December 31, 2022, the company’s debt portfolio was comprised primarily of fixed rate borrowings. The fair market value of the company’s fixed interest rate debt is subject to interest rate risk. Generally, the fair market value of fixed interest rate debt will increase as
27

THERMO FISHER SCIENTIFIC INC.
interest rates fall and decrease as interest rates rise. The total estimated fair value of the company’s debt at December 31, 2022 was $30.29 billion (Note 14). Fair values were determined from available market prices using current interest rates and terms to maturity. If interest rates were to decrease by 100 basis points, the fair value of the company’s debt at December 31, 2022 would increase by approximately $2.00 billion. If interest rates were to increase by 100 basis points, the fair value of the company’s debt at December 31, 2022 would decrease by approximately $1.75 billion.
In addition, interest rate changes would result in a change in the company’s interest expense due to variable-rate debt instruments including swap arrangements. In 2022, a 100 basis point increase in interest rates on the swap arrangements and variable-rate debt would have increased the company’s annual pre-tax interest expense by approximately $35 million.
Currency Exchange Rates
The company views its investment in international subsidiaries with a functional currency other than the U.S. dollar as permanent. The company’s investment in international subsidiaries is sensitive to fluctuations in currency exchange rates. The functional currencies of the company’s international subsidiaries are principally denominated in euro, British pounds sterling, Swedish krona, Canadian dollars, Norwegian kroner and Danish kroner. The effect of a change in the period ending currency exchange rates on the company’s net investment in international subsidiaries is reflected in the “accumulated other comprehensive items” component of shareholders’ equity. The company also uses foreign currency-denominated debt to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A 10% depreciation in year-end 2022 functional currencies, relative to the U.S. dollar, would result in a reduction of shareholders’ equity of approximately $1.45 billion.
The fair value of forward currency-exchange contracts is sensitive to changes in currency exchange rates. The fair value of forward currency-exchange contracts is the estimated amount that the company would pay or receive upon termination of the contract, taking into account the change in currency exchange rates. A 10% depreciation in year-end 2022 non-functional currency exchange rates related to the company’s contracts would result in an additional unrealized loss on forward currency-exchange contracts of $9 million. A 10% appreciation in year-end 2022 non-functional currency exchange rates related to the company’s contracts would result in an unrealized gain on forward currency-exchange contracts of $9 million. The unrealized gains or losses on forward currency-exchange contracts resulting from changes in currency exchange rates are expected to approximately offset losses or gains on the exposures being hedged.
Certain of the company’s cash and cash equivalents are denominated in currencies other than the functional currency of the depositor and are sensitive to changes in currency exchange rates. A 10% depreciation in the related year-end 2022 non-functional currency exchange rates applied to such cash balances would result in a negative impact of $21 million on the company’s net income.
Item 8.    Financial Statements and Supplementary Data
This data is submitted as a separate section to this report. See Item 15 “Exhibits and Financial Statement Schedules.”
Item 9.    Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Not applicable.
Item 9A.    Controls and Procedures
Management’s Evaluation of Disclosure Controls and Procedures
The company’s management, with the participation of the company’s chief executive officer and chief financial officer, has evaluated the effectiveness of the company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation, the company’s chief executive officer and chief financial officer concluded that, as of the end of such period, the company’s disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control over Financial Reporting
There have been no changes in the company’s internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the fiscal quarter ended December 31, 2022, that have materially affected or are reasonably likely to materially affect the company’s internal control over financial reporting.
28

THERMO FISHER SCIENTIFIC INC.
Management’s Annual Report on Internal Control Over Financial Reporting
The company’s management, including the company’s chief executive officer and chief financial officer, is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. The company’s management conducted an assessment of the effectiveness of the company’s internal control over financial reporting as of December 31, 2022 based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this assessment, the company’s management concluded that, as of December 31, 2022, the company’s internal control over financial reporting was effective.
The company’s independent registered public accounting firm, PricewaterhouseCoopers LLP, has audited the effectiveness of the company’s internal control over financial reporting as of December 31, 2022, as stated in their report that appears on page F-2 of this Annual Report on Form 10-K.
Item 9B.    Other Information
On February 22, 2023, the Board of Directors of the company amended and restated the company’s By-Laws, effective immediately, to conform the By-laws to the Securities and Exchange Commission’s universal proxy rules contained in Rule 14a-19 under the Securities Exchange Act of 1934, and certain 2022 amendments to the General Corporation Law of the State of Delaware (the DGCL). The amendments to the By-laws include additions to Article I, Section 9 to implement the requirements of Rule 14a-19 regarding the nomination and solicitation of proxies for director candidates. The amendments to the By-laws also include revisions to Article I, Sections 4 and 8 to conform with the 2022 DGCL amendments. The foregoing description of the amendments to the By-laws does not purport to be complete and is qualified in its entirety by reference to the full text of the By-laws, as amended and restated, a copy of which is attached as Exhibit 3.4 and incorporated by reference herein.
On February 22, 2023, the company entered into a consulting agreement with Mark P. Stevenson, former Executive Vice President and Chief Operating Officer of the company, relating to services that Mr. Stevenson will provide to the company. Under the consulting agreement, which has a term ending March 1, 2024, Mr. Stevenson will serve on the company’s Scientific Advisory Board and will also provide ongoing advice and services as requested by the company. During the term of the consulting agreement, Mr. Stevenson will receive compensation of $8,000 per month. The agreement also contains provisions that restrict Mr. Stevenson’s ability during the term of the consulting agreement (i) to work for or provide consulting services to, any competitor of the company, and (ii) to solicit for hire employees or consultants of the company or to solicit customers or clients of the company.
Item 9C.     Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not applicable.
PART III
Item 10.    Directors, Executive Officers and Corporate Governance
The information with respect to directors required by this Item will be contained in our definitive proxy statement to be filed with the SEC not later than 120 days after the close of business of the fiscal year (2023 Definitive Proxy Statement) including under “Corporate governance,” and is incorporated in this report by reference.
The information with respect to executive officers required by this Item is included in Item 1 of Part I of this report.
The other information required by this Item will be contained in our 2023 Definitive Proxy Statement including under “Corporate governance,” and is incorporated in this report by reference.
Item 11.    Executive Compensation
The information required by this Item will be contained in our 2023 Definitive Proxy Statement including under “Corporate governance,” and “Executive compensation,” and is incorporated in this report by reference.
Item 12.    Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The information required by this Item will be contained in our 2023 Definitive Proxy Statement including under “Information about stock ownership,” and is incorporated in this report by reference.
29

THERMO FISHER SCIENTIFIC INC.
Item 13.    Certain Relationships and Related Transactions, and Director Independence
The information required by this Item will be contained in our 2023 Definitive Proxy Statement including under “Corporate governance,” and is incorporated in this report by reference.
Item 14.    Principal Accountant Fees and Services
The information required by this Item will be contained in our 2023 Definitive Proxy Statement including under “Audit matters,” and is incorporated in this report by reference.
PART IV
Item 15.    Exhibits and Financial Statement Schedules
(a) The following documents are filed as part of this report:
(1) Consolidated Financial Statements (see Index on page F-1 of this report)
(2) All schedules are omitted because they are not applicable or not required, or because the required information is included either in the consolidated financial statements or in the notes thereto.
(b) Exhibits
See the Exhibit Index on page 31.
Item 16.    Form 10-K Summary
None.
30

THERMO FISHER SCIENTIFIC INC.
EXHIBIT INDEX

Exhibit Number Description of Exhibit
2.1
Agreement and Plan of Merger, dated as of April 15, 2021, by and among Thermo Fisher Scientific Inc., Powder Acquisition Corp. and PPD, Inc. (filed as Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed April 16, 2021 [File No. 1-8002] and incorporated in this document by reference).
3.1
Amended and Restated Certificate of Incorporation of the Registrant (filed as Exhibit 3.1 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2005 [File No. 1-8002] and incorporated in this document by reference).
3.2
Amendment to Thermo Fisher Scientific Inc.’s Third Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed November 14, 2006 [File No. 1-8002] and incorporated in this document by reference).
3.3
Certificate of Elimination of the Series B Junior Participating Preferred Stock of the Company, dated November 13, 2015 (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed November 16, 2015 [File No. 1-8002] and incorporated in this document by reference).
3.4
The Registrant agrees, pursuant to Item 601(b)(4)(iii)(A) of Regulation S-K, to furnish to the Commission, upon request, a copy of each instrument with respect to long-term debt of the Registrant or its consolidated subsidiaries.
4.1
Indenture dated as of November 20, 2009 between the Company and The Bank of New York Mellon Trust Company, N.A. (filed as Exhibit 99.1 to the Registrant’s Current Report on Form 8-K filed November 20, 2009 [File No. 1-8002] and incorporated in this document by reference).
4.2
Sixth Supplemental Indenture, dated as of December 11, 2013, between the Company and The Bank of New York Mellon Trust Company, N.A. (filed as Exhibit 99.2 to the Registrant’s Current Report on Form 8-K filed December 11, 2013 [File No. 1-8002] and incorporated in this document by reference).
4.3
Eighth Supplemental Indenture, dated as of November 24, 2014, among the Company, The Bank of New York Mellon Trust Company, N.A., as trustee, and The Bank of New York Mellon, London Branch, as paying agent (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed November 24, 2014 [File No. 1-8002] and incorporated in this document by reference).
4.4
Thirteenth Supplemental Indenture, dated as of September 12, 2016, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed September 12, 2016 [File No. 1-8002] and incorporated in this document by reference).
4.5
Fifteenth Supplemental Indenture, dated as of March 16, 2017, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed March 16, 2017 [File No. 1-8002] and incorporated in this document by reference).
4.6
Sixteenth Supplemental Indenture, dated as of July 24, 2017, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed July 24, 2017 [File No. 1-8002] and incorporated in this document by reference).
4.7
Seventeenth Supplemental Indenture, dated as of August 14, 2017, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed August 14, 2017 [File No. 1-8002] and incorporated in this document by reference).
4.8
Eighteenth Supplemental Indenture, dated as of September 30, 2019, between the Company, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed September 30, 2019 [File No. 1-8002] and incorporated in this document by reference).
4.9
Nineteenth Supplemental Indenture, dated as of October 8, 2019, between the Company, and the Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed October 8, 2019 [File No. 1-8002] and incorporated in this document by reference).
4.10
Twenty-First Supplemental Indenture, dated as of April 2, 2020, between the Company, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed April 2, 2020 [File No. 1-8002] and incorporated in this document by reference).
4.11
Twenty-Second Supplemental Indenture, dated as of August 23, 2021, between the Company, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed August 23, 2021 [File No. 1-8002] and incorporated in this document by reference).
4.12
Twenty-Third Supplemental Indenture, dated as of October 22, 2021, between the Company, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed October 22, 2021 [File No. 1-8002] and incorporated in this document by reference).
4.13
Twenty-Fourth Supplemental Indenture, dated as of October 20, 2022, between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed October 20, 2022 [File No. 1-8002] and incorporated in this document by reference).
4.14
Twenty-Fifth Supplemental Indenture, dated as of November 21, 2022, between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed November 21, 2022 [File No. 1-8002] and incorporated in this document by reference).
4.15
Twenty-Sixth Supplemental Indenture, dated as of November 21, 2022, between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.3 to the Registrant’s Current Report on Form 8-K filed November 21, 2022 [File No. 1-8002] and incorporated in this document by reference).
31

THERMO FISHER SCIENTIFIC INC.
EXHIBIT INDEX

Exhibit Number Description of Exhibit
4.16
Indenture, dated as of August 9, 2016, among Thermo Fisher International, as issuer, the Company, as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed August 9, 2016 [File No. 1-8002] and incorporated in this document by reference).
4.17
Third Supplemental Indenture, dated as of October 18, 2021, among Thermo Fisher Scientific (Finance I) B.V. (Thermo Fisher International), as issuer, the Company, as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed October 18, 2021 [File No. 1-8002] and incorporated in this document by reference).
4.18
4.19
10.1
Thermo Fisher Scientific Inc. Deferred Compensation Plan for Directors of the Registrant, as amended and restated effective November 10, 2006 (filed as Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 29, 2007 [File No. 1‑8002] and incorporated in this document by reference).*
10.2
Thermo Electron Corporation Deferred Compensation Plan, effective November 1, 2001 (filed as Exhibit 10.13 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 29, 2001 [File No. 1-8002] and incorporated in this document by reference).*
10.3
Form of Amended and Restated Indemnification Agreement between the Registrant and its directors and officers (filed as Exhibit 10.2 to the Registrant’s Registration Statement on Form S-4 [Reg. No. 333-90661] and incorporated in this document by reference).*
10.4
Summary of Thermo Fisher Scientific Inc. Annual Non-Management Director Compensation (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed February 24, 2022 [File No. 1-8002] and incorporated in this document by reference).*
10.5
Form of Noncompetition Agreement between the Registrant and certain key employees and executive officers, effective as of January 1, 2009 (filed as Exhibit 10.25 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2009 [File No. 1-8002] and incorporated in this document by reference).*
10.6 Retirement Plan for Non-Employee Directors of Fisher Scientific International Inc. (filed as Exhibit 10.12 to Fisher Scientific International Inc.’s Annual Report on Form 10-K for the year ended December 31, 1992 [File No. 1-10920] and incorporated in this document by reference).*
10.7
First Amendment to the Fisher Scientific International Inc. Retirement Plan for Non-Employee Directors (filed as Exhibit 10.04 to Fisher Scientific International Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2005 [File No. 1-10920] and incorporated in this document by reference).*
10.8
Amendment to Retirement Plan for Non-Employee Directors of Fisher Scientific International Inc. (filed as Exhibit 10.02 to Fisher Scientific International Inc.’s Current Report on Form 8-K filed March 7, 2006 [File No. 1-10920] and incorporated in this document by reference).*
10.9
Thermo Fisher Scientific Inc. Amended and Restated 2005 Deferred Compensation Plan, effective January 1, 2020 (filed as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 27, 2020 [File No. 1-8002] and incorporated in this document by reference).*
10.10
2009 Restatement of Executive Severance Agreement, between Marc N. Casper and the Registrant, dated November 21, 2009 (filed as Exhibit 10.5 to the Registrant’s Current Report on Form 8-K filed November 25, 2009 [File No. 1-8002] and incorporated in this document by reference).*
10.11
Executive Change In Control Retention Agreement, between Marc N. Casper and the Registrant, dated November 21, 2009 (filed as Exhibit 10.6 to the Registrant’s Current Report on Form 8-K filed November 25, 2009 [File No. 1-8002] and incorporated in this document by reference).*
10.12
Noncompetition Agreement, between Marc N. Casper and the Registrant, dated November 21, 2009 (filed as Exhibit 10.7 to the Registrant’s Current Report on Form 8-K filed November 25, 2009 [File No. 1-8002] and incorporated in this document by reference).*
10.13
Amendment No. 1 to 2009 Restatement of Executive Severance Agreement, dated February 25, 2010, between the Registrant and Marc N. Casper (filed as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed February 25, 2010 [File No. 1-8002] and incorporated in this document by reference).*
10.14
Amendment No. 2 to 2009 Restatement of Executive Severance Agreement, dated November 30, 2010, between the Registrant and Marc N. Casper (filed as Exhibit 10.55 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2010 [File No. 1-8002] and incorporated in this document by reference).*
10.15
Amendment No. 1 to Executive Change In Control Retention Agreement, dated November 30, 2010, between Marc N. Casper and the Registrant (filed as Exhibit 10.56 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2010 [File No. 1-8002] and incorporated in this document by reference).*
10.16
Amendment No. 2 to Executive Change in Control Retention Agreement, dated March 16, 2018, between Marc N. Casper and the Registrant (filed as Exhibit 10.3 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 [File No. 1-8002] and incorporated in this document by reference).*
32

THERMO FISHER SCIENTIFIC INC.
EXHIBIT INDEX

Exhibit Number Description of Exhibit
10.17
Form of Executive Change in Control Retention Agreement for Officers (other than Marc N. Casper) (filed as Exhibit 10.2 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 [File No. 1-8002] and incorporated in this document by reference).*
10.18
Form of Thermo Fisher Scientific Inc.’s Restricted Stock Unit Agreement for Directors (filed as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended April 2, 2011 [File No. 1-8002] and incorporated in this document by reference).*
10.19
Form of Nonstatutory Stock Option Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective February 26, 2013 (filed as Exhibit 10.5 to the Registrant’s Current Report on Form 8-K filed February 27, 2013 [File No. 1-8002] and incorporated in this document by reference).*
10.20
Thermo Fisher Scientific Inc. 2013 Stock Incentive Plan (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed May 23, 2013 [File No. 1-8002] and incorporated in this document by reference).*
10.21
Supplemental Executive Retirement Plan effective as of December 31, 2005, as amended and restated as of August 28, 2006 (filed as Exhibit 10.3 to Applera Corporation’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2006 [File No. 1-04389] and incorporated in this document by reference).*
10.22
Amendment to Supplemental Executive Retirement Plan, effective as of January 1, 2010 (filed as Exhibit 10.1 to Life Technologies Corporation’s Current Report on Form 8-K filed December 18, 2009 [File No. 000-25317] and incorporated in this document by reference).*
10.23
Noncompetition Agreement between the Registrant and Mark P. Stevenson, dated September 10, 2015 (filed as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 26, 2015 [File No. 1-8002] and incorporated in this document by reference).*
10.24
Form of Thermo Fisher Scientific Inc.’s Nonstatutory Stock Option Agreement for Officers (filed as Exhibit 10.44 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2016 [File No. 1-8002] and incorporated in this document by reference).*
10.25
Patheon N.V. 2016 Omnibus Incentive Plan (filed as Exhibit 10.2 to the Current Report on Form 8-K filed by Patheon N.V. on July 26, 2016 [File No. 001-37837] and incorporated in this document by reference).*
10.26
Amendment to Patheon N.V. 2016 Omnibus Incentive Plan, dated March 7, 2017 (filed as Exhibit 4.5 to the Registrant's Registration Statement on Form S-8 filed August 29, 2017 [File No. 1-8002] and incorporated in this document by reference).*
10.27
Amendment to Patheon N.V. 2016 Omnibus Incentive Plan, dated August 23, 2017 (filed as Exhibit 4.6 to the Registrant's Registration Statement on Form S-8 filed August 29, 2017 [File No. 1-8002] and incorporated in this document by reference).*
10.28
10.29
Letter Agreement between the Registrant and Michel Lagarde dated August 28, 2017 (filed as Exhibit 10.39 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.30
Option Agreement Under the Patheon N.V. 2016 Omnibus Incentive Plan between Patheon N.V. and Michel Lagarde dated July 20, 2016 (filed as Exhibit 10.40 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.31
Option Agreement Under the Patheon N.V. 2016 Omnibus Incentive Plan between Patheon N.V. and Michel Lagarde dated March 23, 2017 (filed as Exhibit 10.42 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.32
Thermo Fisher Scientific Inc. Executive Severance Policy (filed as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 29, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.33
Form of Noncompetition Agreement between the Registrant and certain key employees and executive officers (filed as Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 29, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.34
Form of Thermo Fisher Scientific Inc.’s Performance Restricted Stock Unit Agreement effective as of February 25, 2020 (filed as Exhibit 10.45 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.35
Form of Thermo Fisher Scientific Inc.’s Restricted Stock Unit Agreement effective as of February 25, 2020 (filed as Exhibit 10.46 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.36
Form of Thermo Fisher Scientific Inc.’s Nonstatutory Stock Option Agreement for Officers effective as of February 25, 2020 (filed as Exhibit 10.47 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
33

THERMO FISHER SCIENTIFIC INC.
EXHIBIT INDEX

Exhibit Number Description of Exhibit
10.37
Form of Performance Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 25, 2020 (filed as Exhibit 10.48 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.38
Form of Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 25, 2020 (filed as Exhibit 10.49 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.39
Form of Nonstatutory Stock Option Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 25, 2020 (filed as Exhibit 10.50 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.40
Form of Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper (filed as Exhibit 10.47 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020 [File No. 1-8002] and incorporated in this document by reference).*
10.41
Form of Performance Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper (filed as Exhibit 10.48 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020 [File No. 1-8002] and incorporated in this document by reference).*
10.42
Form of Thermo Fisher Scientific Inc.’s Performance Restricted Stock Unit Agreement (filed as Exhibit 10.49 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020 [File No. 1-8002] and incorporated in this document by reference).*
10.43
PPD, Inc. 2020 Omnibus Incentive Plan (filed as Exhibit 10.38 to PPD Inc.’s Form S-1/A filed January 27, 2020 [File No. 333-235860] and incorporated in this document by reference).*
10.44
Consulting Agreement between the Registrant and Mark P. Stevenson, dated February 24, 2022 (filed as Exhibit 10.49 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2021 [File No. 1-8002] and incorporated in this document by reference).*
10.45
10.46
10.47
21
22
23.1
31.1
31.2
32.1
32.2
101.INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH XBRL Taxonomy Extension Schema Document.
101.CAL XBRL Taxonomy Calculation Linkbase Document.
101.DEF XBRL Taxonomy Definition Linkbase Document.
101.LAB XBRL Taxonomy Label Linkbase Document.
101.PRE XBRL Taxonomy Presentation Linkbase Document.
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
_______________________
*Indicates management contract or compensatory plan, contract or arrangement.
** Certification is not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. Such certification is not deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act except to the extent that the registrant specifically incorporates it by reference.
34

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: February 23, 2023 THERMO FISHER SCIENTIFIC INC.
By: /s/ Marc N. Casper
Marc N. Casper
Chairman, President and Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated, as of February 23, 2023.
By:
 /s/ Marc N. Casper
By:
 /s/ R. Alexandra Keith
Marc N. Casper
 R. Alexandra Keith
Chairman, President and Chief Executive Officer Director
(Principal Executive Officer)
By:
 /s/ Stephen Williamson
By:
 /s/ Jim P. Manzi
Stephen Williamson Jim P. Manzi
Senior Vice President and Chief Financial Officer Director
(Principal Financial Officer)
By:
 /s/ Joseph R. Holmes
By:
 /s/ James C. Mullen
Joseph R. Holmes James C. Mullen
Vice President and Chief Accounting Officer Director
(Principal Accounting Officer)
By:
 /s/ Nelson J. Chai
By:
/s/ Lars R. Sørensen
Nelson J. Chai
Lars R. Sørensen
Director Director
By:
 /s/ Ruby R. Chandy
By:
/s/ Debora L. Spar
Ruby R. Chandy
Debora L. Spar
Director Director
By:
 /s/ C. Martin Harris
By:
 /s/ Scott M. Sperling
C. Martin Harris Scott M. Sperling
Director Director
By:
 /s/ Tyler E. Jacks By: /s/ Dion J. Weisler
Tyler E. Jacks Dion J. Weisler
Director Director

35

THERMO FISHER SCIENTIFIC INC.
INDEX OF CONSOLIDATED FINANCIAL STATEMENTS
 
The following Consolidated Financial Statements of the Registrant and its subsidiaries are required to be included in Item 15:
  Page
   
Report of Independent Registered Public Accounting Firm (PCAOB ID 238)
Consolidated Balance Sheet as of December 31, 2022 and 2021
Consolidated Statement of Income for the years ended December 31, 2022, 2021 and 2020
Consolidated Statement of Comprehensive Income for the years ended December 31, 2022, 2021 and 2020
Consolidated Statement of Cash Flows for the years ended December 31, 2022, 2021 and 2020
Consolidated Statement of Redeemable Noncontrolling Interest and Equity for the years ended December 31, 2022, 2021 and 2020
Notes to Consolidated Financial Statements

F-1

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Shareholders of Thermo Fisher Scientific Inc.
Opinions on the Financial Statements and Internal Control over Financial Reporting
We have audited the accompanying consolidated balance sheet of Thermo Fisher Scientific Inc. and its subsidiaries (the “Company”) as of December 31, 2022 and 2021, and the related consolidated statements of income, of comprehensive income, of redeemable noncontrolling interest and equity and of cash flows for each of the three years in the period ended December 31, 2022, including the related notes (collectively referred to as the “consolidated financial statements”). We also have audited the Company's internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.
Basis for Opinions
The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Annual Report on Internal Control Over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.
Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely
F-2

detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Critical Audit Matters

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
Income taxes
As described in Note 8 to the consolidated financial statements, the Company’s provision for income taxes for the year ended December 31, 2022 was $703 million. The Company has deferred tax liabilities, net, of $1,984 million (including a valuation allowance of $1,322 million) and unrecognized tax benefits of $572 million as of December 31, 2022. As disclosed by management, the Company operates in numerous countries under many legal forms and, as a result, is subject to the jurisdiction of numerous domestic and non-U.S. tax authorities, as well as to tax agreements and treaties among these governments. Determination of taxable income in any jurisdiction requires management to interpret the related tax laws and regulations and to use estimates and assumptions regarding significant future events, such as the amount, timing and character of deductions, permissible revenue recognition methods under the tax law and the sources and character of income and tax credits. Management assesses income tax positions and records tax benefits for all years subject to examination based upon management’s evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, management has recorded the largest amount of tax benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements. Management estimates the degree to which tax assets will result in a benefit, after consideration of all positive and negative evidence, and provides a valuation allowance for tax assets that it believes will more likely than not go unused. In situations in which management has been able to determine that the Company’s deferred tax assets will be realized, that determination generally relies on future reversals of taxable temporary differences and expected future taxable income. If it becomes more likely than not that a tax asset will be used, management reverses the related valuation allowance.
The principal considerations for our determination that performing procedures relating to income taxes is a critical audit matter are (i) the significant judgment by management when interpreting the numerous and complex tax laws and regulations as it relates to determining the provision for income taxes, deferred tax assets and liabilities, including the valuation allowance, and liabilities for unrecognized tax benefits, (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence related to the provision for income taxes, deferred tax assets and liabilities, including the valuation allowance, and liabilities for unrecognized tax benefits, and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the provision for income taxes, deferred tax assets and liabilities, including the valuation allowance, and liabilities for unrecognized tax benefits. These procedures also included, among others (i) testing the accuracy of the provision for income taxes, including the rate reconciliation and permanent and temporary differences, (ii) evaluating whether the data utilized in the calculations of the provision for income taxes, deferred tax assets and liabilities, and liabilities for unrecognized tax benefits were appropriate and consistent with evidence obtained in other areas of the audit, (iii) evaluating management’s assessment of the realizability of deferred tax assets on a jurisdictional basis, (iv)
F-3

evaluating the identification of liabilities for unrecognized tax benefits and the reasonableness of the more likely than not determination in consideration of court decisions, legislative actions, statutes of limitations, and developments in tax examinations by jurisdiction, (v) testing the calculation of the liability for unrecognized tax benefits by jurisdiction, including estimates of the amount of income tax benefit expected to be sustained, and (vi) evaluating the adequacy of the Company’s disclosures. Professionals with specialized skill and knowledge were used to assist in evaluating the reasonableness of management’s judgments and estimates related to the application of foreign and domestic tax laws and regulations.


/s/PricewaterhouseCoopers LLP
Boston, Massachusetts
February 23, 2023

We have served as the Company’s auditor since 2002.
F-4

THERMO FISHER SCIENTIFIC INC.
CONSOLIDATED BALANCE SHEET
  December 31, December 31,
(In millions except share and per share amounts) 2022 2021
Assets
Current assets:
Cash and cash equivalents $ 8,524  $ 4,477 
Accounts receivable, less allowances of $189 and $150
 8,115  7,977 
Inventories 5,634  5,051 
Contract assets, net 1,312  968 
Other current assets 1,644  1,640 
Total current assets
 25,229  20,113 
Property, plant and equipment, net 9,280  8,333 
Acquisition-related intangible assets, net 17,442  20,113 
Other assets 4,007  4,640 
Goodwill 41,196  41,924 
Total assets
 $ 97,154  $ 95,123 
Liabilities, redeemable noncontrolling interest and equity
Current liabilities:
Short-term obligations and current maturities of long-term obligations $ 5,579  $ 2,537 
Accounts payable 3,381  2,867 
Accrued payroll and employee benefits 2,095  2,427 
Contract liabilities 2,601  2,655 
Other accrued expenses 3,354  2,950 
Total current liabilities
 17,010  13,436 
Deferred income taxes 2,849  3,837 
Other long-term liabilities 4,238  4,540 
Long-term obligations 28,909  32,333 
Commitments and contingencies (Note 12)
Redeemable noncontrolling interest 116  122 
Equity:
Thermo Fisher Scientific Inc. shareholders’ equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 440,668,112 and 439,154,741 shares issued
 441  439 
Capital in excess of par value 16,743  16,174 
Retained earnings 41,910  35,431 
Treasury stock at cost, 50,157,275 and 44,720,112 shares
 (12,017) (8,922)
Accumulated other comprehensive items (3,099) (2,329)
Total Thermo Fisher Scientific Inc. shareholders’ equity 43,978  40,793 
Noncontrolling interests 54  62 
Total equity
 44,032  40,855 
Total liabilities, redeemable noncontrolling interest and equity
 $ 97,154  $ 95,123 

The accompanying notes are an integral part of these consolidated financial statements.
F-5

THERMO FISHER SCIENTIFIC INC.
CONSOLIDATED STATEMENT OF INCOME
  Year Ended
  December 31, December 31, December 31,
(In millions except per share amounts) 2022 2021 2020
Revenues
Product revenues
 $ 28,548  $ 30,361  $ 25,306 
Service revenues
 16,367  8,850  6,912 
Total revenues
 44,915  39,211  32,218 
Costs and operating expenses:
Cost of product revenues
 14,247  13,594  11,407 
Cost of service revenues
 11,697  5,979  4,807 
Selling, general and administrative expenses
 8,993  8,007  6,930 
Research and development expenses
 1,471  1,406  1,181 
Restructuring and other costs
 114  197  99 
Total costs and operating expenses
 36,522  29,183  24,424 
Operating income 8,393  10,028  7,794 
Interest income 272  43  65 
Interest expense (726) (536) (553)
Other income/(expense)
 (104) (694) (76)
Income before income taxes
 7,835  8,841  7,230 
Provision for income taxes
 (703) (1,109) (850)
Equity in earnings/(losses) of unconsolidated entities (172) (4) (3)
Net income 6,960  7,728  6,377 
Less: net income attributable to noncontrolling interests and redeemable noncontrolling interest 10  3  2 
Net income attributable to Thermo Fisher Scientific Inc. $ 6,950  $ 7,725  $ 6,375 
Earnings per share attributable to Thermo Fisher Scientific Inc.
Basic
 $ 17.75  $ 19.62  $ 16.09 
Diluted
 $ 17.63  $ 19.46  $ 15.96 
Weighted average shares
Basic
 392  394  396 
Diluted
 394  397  399 

The accompanying notes are an integral part of these consolidated financial statements.

F-6

THERMO FISHER SCIENTIFIC INC.
 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
  Year Ended
  December 31, December 31, December 31,
(In millions) 2022 2021 2020
Comprehensive income
Net income
 $ 6,960  $ 7,728  $ 6,377 
Other comprehensive items:
Currency translation adjustment:
Currency translation adjustment (net of tax provision (benefit) of $173, $231 and $(221))
 (822) 373  (118)
Unrealized gains and losses on hedging instruments:
Unrealized losses on hedging instruments (net of tax benefit of $0, $0 and $20)
 —  —  (65)
Reclassification adjustment for losses included in net income (net of tax benefit of $1, $17 and $14)
 2  56  45 
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the period (net of tax provision (benefit) of $9, $11 and $(1))
 38  36  (8)
Amortization of net loss and prior service benefit included in net periodic pension cost (net of tax benefit of $3, $6 and $4)
 5  13  18 
Total other comprehensive items
 (777) 478  (128)
Comprehensive income
 6,183  8,206  6,249 
Less: comprehensive income attributable to noncontrolling interests and redeemable noncontrolling interest
 3  2  2 
Comprehensive income attributable to Thermo Fisher Scientific Inc.
 $ 6,180  $ 8,204  $ 6,247 

The accompanying notes are an integral part of these consolidated financial statements.

F-7

THERMO FISHER SCIENTIFIC INC.
CONSOLIDATED STATEMENT OF CASH FLOWS
Year Ended
December 31, December 31, December 31,
(In millions) 2022 2021 2020
Operating activities
Net income
 $ 6,960  $ 7,728  $ 6,377 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property, plant and equipment
 986  831  658 
Amortization of acquisition-related intangible assets
 2,395  1,761  1,667 
Change in deferred income taxes
 (995) (647) (552)
Stock-based compensation
 307  230  196 
Loss on early extinguishment of debt 26  767  — 
Other non-cash expenses
 524  190  338 
Changes in assets and liabilities, excluding the effects of acquisitions and disposition:
Accounts receivable
 (430) (204) (1,302)
Inventories
 (825) (1,065) (508)
Accounts payable
 648  479  59 
Contributions to retirement plans
 (41) (34) (96)
Other (401) (724) 1,452 
Net cash provided by operating activities
 9,154  9,312  8,289 
Investing activities
      
Acquisitions, net of cash acquired
 (39) (19,395) (38)
Purchase of property, plant and equipment
 (2,243) (2,523) (1,474)
Proceeds from sale of property, plant and equipment
 24  20  8 
Other investing activities, net
 99  (34) (6)
Net cash used in investing activities
 (2,159) (21,932) (1,510)
Financing activities
Net proceeds from issuance of debt
 3,193  18,137  3,464 
Repayment of debt
 (375) (11,738) (710)
Proceeds from issuance of commercial paper
 1,526  2,512  383 
Repayments of commercial paper
 (3,690) —  (387)
Purchases of company common stock
 (3,000) (2,000) (1,500)
Dividends paid
 (455) (395) (337)
Other financing activities, net
 (9) 65  46 
Net cash (used in) provided by financing activities
 (2,810) 6,581  959 
Exchange rate effect on cash
 (139) 194  176 
Increase (decrease) in cash, cash equivalents and restricted cash
 4,046  (5,845) 7,914 
Cash, cash equivalents and restricted cash at beginning of year
 4,491  10,336  2,422 
Cash, cash equivalents and restricted cash at end of year
 $ 8,537  $ 4,491  $ 10,336 
The accompanying notes are an integral part of these consolidated financial statements.
F-8

THERMO FISHER SCIENTIFIC INC.
CONSOLIDATED STATEMENT OF REDEEMABLE NONCONTROLLING INTEREST AND EQUITY
  Redeemable Noncontrolling Interest Common Stock Capital in Excess of Par Value Retained Earnings Treasury Stock Accumulated Other Comprehensive Items Total
Thermo Fisher Scientific Inc. Shareholders’ Equity		 Noncontrolling Interests Total Equity
(In millions) Shares Amount Shares Amount
Balance at December 31, 2019 $ —  434  $ 434  $ 15,064  $ 22,092  36  $ (5,236) $ (2,679) $ 29,675  $ 9  $ 29,684 
Cumulative effect of accounting changes
 —  —  —  —  (1) —  —  —  (1) —  (1)
Issuance of shares under employees' and directors' stock plans
 —  3  3  319  —  —  (82) —  240  —  240 
Stock-based compensation
 —  —  —  196  —  —  —  —  196  —  196 
Purchases of company common stock
 —  —  —  —  —  4  (1,500) —  (1,500) —  (1,500)
Dividends declared ($0.88 per share)
 —  —  —  —  (350) —  —  —  (350) —  (350)
Net income
 —  —  —  —  6,375  —  —  —  6,375  2  6,377 
Other comprehensive items
 —  —  —  —  —  —  —  (128) (128) —  (128)
Contributions from (distributions to) noncontrolling interests —  —  —  —  —  —  —  —  —  (1) (1)
Balance at December 31, 2020 —  437  437  15,579  28,116  40  (6,818) (2,807) 34,507  10  34,517 
Issuance of shares under employees' and directors' stock plans
 —  2  2  324  —  1  (104) —  222  —  222 
Stock-based compensation
 —  —  —  230  —  —  —  —  230  —  230 
Purchases of company common stock
 —  —  —  —  —  4  (2,000) —  (2,000) —  (2,000)
Dividends declared ($1.04 per share)
 —  —  —  —  (410) —  —  —  (410) —  (410)
Recognition upon acquisition 122  —